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Abstract 
 
Aberrant Wnt/Beta-Catenin signaling is observed in a wide spectrum of 
human malignancies. Activation of this pathway is involved in colon and 
ovarian cancer. Therefore, inhibitors of the TCF4/Beta-Catenin 
interaction are of great potential as antitumor agents. We used the 
recently described protein meta-structure approach to identify novel small 
molecule compounds as binders for Beta-Catenin. The identified ligands 
have been tested for binding with the target protein using 1D 1H-STD, 1D 
AFP NOESY, 2D NOESY and 19F-NMR. The identified binders were 
demonstrated to compete with the authentic Beta-Catenin binding partner 
TCF4.  
In addition, a dynamic combinatorial library has been designed to 
synthesize new ligands for Beta-Catenin. Moreover, 2D & 3D-NMR 
experiments were used to assign the backbone signals of full length TCF4 
and two different truncations at different pH values. The data obtained 
from assignment at pH=4.5 and pH=2 were compared with the predicted 
random coil shifts. Secondary structure propensities were also compared 
which allowed us to estimate changes in secondary structure propensities 
upon pH change. Finally, further structural insight into the TCF4/Beta-
Catenin complex was provided by a combined X-ray crystallography and 
NMR study employing selective lysine reductive-methylation reaction. 
To highlight the importance of our work, the resulting prospects for the 
development of new powerful anticancer drugs with a high safety profile 
will also be discussed. 
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1.1. Chemistry of Proteins 
Proteins are polypeptides of varying length consist of amino acids linked 
together via peptide bond. The binding between two amino acids through the 
addition-elimination interaction between the carboxylic group of one amino acid and 
the amino group of the other generates the peptide bond. Peptide bond is 
characterized of being planar due to amide resonance with only 2 degrees of freedom 
(phi and psi torsion angles). 
Proteins consist of one or more polypeptide chains. The number and sequence of 
amino acids differs from one protein to the other.  
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FIG. 1 Peptide bond formation. 
 
Proteins are complex macromolecules and to account for this enormous complexity, 
Linderstrom-Lang1 described his classical schemes in which he proposed a four levels 
system for the protein structure: primary, secondary, tertiary and quaternary structure.  
a- Primary structure gives just the linear amino acid sequence. In a study by 
Sobolevsky et. al.2, they demonstrated the presence of conserved octamers in most of 
the sequenced genomes. In the species where these conserved octamers aren’t found, 
analogs of them with one or two residues different are detected. Based on this, it 
could be predicted that the conserved sequence and the modules they represent, 
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should serve as a basis for molecular reconstruction of the last common ancestor of 
modern species. 
 
FIG. 2 Protein primary structure.  
 
b- The secondary structure is the next ‘level up’ in protein structure that arises 
from the primary structure. Hydrogen bonds play the main rule in the type of 
secondary structure that a protein possesses. The main two secondary elements of 
proteins are; α-helix and ß-sheet. In α-helix3, each N-H group forms a hydrogen bond 
to the backbone C=O of an amino acid that is 4 residues earlier. This H-bonding helps 
in directing many polypeptides to take the cylindrical shape that characterizes this 
secondary structure. 
 
FIG. 3 Protein α-helix secondary structure. 
 
In ß-sheet, the chain of amino acids in the polypeptide folds back and forth upon itself 
instead of forming a helix. This type of folding exposes hydrogen atoms, which can 
lead to extensive mesh of hydrogen bonding. 
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FIG. 4 Protein ß-sheet secondary structure showing 2 antiparallel beta-strands. 
 
c- The tertiary structure is the native (3D) conformation and the overall folding 
pattern of the protein. Once the polypeptide has a definite secondary structure, the 
side chain of each amino acid is positioned in a certain way. Hence, if additional 
chemical bonds (e.g. hydrogen bonds, covalent bonds or other atomic interactions) are 
taking place, the polypeptide chain will accommodate to this and gives a unique 3D 
structure. 
The tertiary folding of the polypeptide forms exposed regions or grooves in the 
molecule, which may be involved in the binding sites for ligand or other protein.  
In 1976, Levitt and Chothia4 studied the structure of different 31 proteins and showed 
that the arrangement of secondary structure units is statistically significant and these 
secondary units when adjacent in the sequence, they tend to form few number of 
specifically defined folding units. 
 
FIG. 5 Protein from primary to secondary to tertiary structure. (Figure is adapted from web 
site: http://www.cs.nott.ac.uk/~nxk/TEACHING/G6DHLL/COURSEWORK/2003-
2004/courseworks.htm). 
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d- If the protein consists of more than one polypeptide, the organization of 
protein subunits to form an oligomeric arrangement is called the quaternary structure 
(e.g., hemoglobin structure5). The polypeptide subunits bind together either by non-
covalent bonding (mainly hydrophobic interaction) or by covalent linkages.  
 
FIG. 6 Quaternary structure of hemoglobin protein. (PDB entry 2DHB). 
 
1.2. Protein Domain  
Several polypeptide chains fold into two or more parts; each displays α-helix or ß-
sheet secondary structure element. These segments are called domains which 
represent the regions of the polypeptide which can function, and exist independently 
of the rest of the protein6. One protein can have several domains and one domain can 
appear in a variety of different proteins like armadillo repeat domain in catenin 
family. 
 
1.3. Intrinsically disordered proteins  
Intrinsically disordered proteins (IDPs) account for a large scale of eukaryotic 
proteins, as it’s believed that 50% of these proteins contain disordered areas of more 
than 30 amino acids7. In addition, it was found by Fong et al8 that on average three 
quarters of the protein complexes have as much as one third of their residues in the 
unstructured state. IDPs play usually a major rule in the regulatory processes of 
translation, transduction and cell signaling and they are found predominantly in the 
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cell nucleus. While naturally folded proteins have global energy minima, the IDPs fail 
to adopt one single conformation or defined 3D structure9. This unique nature of the 
IDPs is mainly related to the low content of hydrophobic residue chains in the 
sequence, which leads to the absence of a folded core in the IDPs. On the other hand, 
they are rich with high content of polar and charged residues. 
 
FIG. 7 Difference between IDPs and folded proteins in energy minima. While folded ones 
have global energy minima, IDPs sample different conformations without definite 3D 
structure. 
 
Due to this sequence difference, the IDPs have intrinsic lower tendency to form 
aggregates than denatured globular proteins although some IDPs are associated with 
amyloid formation diseases. As most of the globular proteins tend to aggregate when 
there’s change in the solution condition or disruption of the sequence, the IDPs have 
naturally evolved to avoid amyloid formation10.  
Although lacking a definite 3D structure, the IDPs even in the highly unfolded state 
possess secondary structure propensity11. It was shown by Marsh et al7 that in the IDP 
family of synuclein, α-synuclein protein, which is prone to amyloid formation and 
highly related to Parkinson’s disease and amyloid plaques of Alzheimer disease, has 
34% difference in the sequence in the amyloid formation region with the γ-synuclein 
that forms only fibrils at much higher concentration and slower rate. This difference 
in tendency to form amyloid between the two proteins was rationalized based on the 
difference in the secondary structure propensity between them. α-Synuclein has β-
structure propensity in the amyloid-forming region, while γ-synuclein has a tendency 
to form α-helical structure, which could possibly stabilize the intermediate state and 
prevents oligomerization in comparison to the β-structure intermediate in α-synuclein.  
Many IDPs move to more ordered or folded state upon binding to their targets and 
usually this process to be enthalpic driven9. Due to the high capture radius of these 
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proteins for specific binding site, they weakly bind to the targeted protein at large 
distance and then they start to fold as they approach the binding site (fly-casting 
mechanism) which provides a kinetic advantage12. 
 
1.4. Protein Meta-Structure Concept 
The knowledge about the protein chemistry and structure is crucial for 
different fields like health care and biotechnology. The main reason for developing 
meta-structure concept is to have the ability to predict protein structure and possible 
ligands based only on sequence (without knowledge of the secondary or tertiary 
structure of the protein).  
 
 
FIG.8 The protein meta-structure concept. The 3D structure is converted into a topological 
map by calculating the network of amino acids interactions. (a) 3D structure of a protein (b) 
Location of the network including residues Q61–T35–V14–I84– N116–E143. (c) Topological 
map of calculated from the 3D structure (d) Extraction of the parameter (shortest path length 
θ) between residues. (Figure is adapted from Konrat13). 
 
Meta-structure concept was developed by Prof. Robert Konrat13 in 2009. In this 
technique, 3D structure of different protein were taken from PDB, and each 3D is 
converted into a topological map in which each node represent an amino acid and 
each edge indicates a neighborhood between the two residues (neighborhood means 
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that the distances between the Cα-Cα are less than 8 A°). From this topological map, 
the shortest path length connecting two residues in the network quantifies a 
topological parameter called θ. This parameter depends on the primary sequence 
distance between the two amino acids and their nature. Parameter θ is statistically 
evaluated using the PDB14, and stored as a pairwise distribution functions. 
 
Parameter θ is used then alone to calculate the two Meta-structure parameters; 
compactness and secondary structure. Compactness (Ci) is calculated and plotted 
against the residue position. Large compactness values indicate stable part of the 
protein or deeply buried domain in the structure. While small values indicate flexible 
loop or unstructured region. On the other hand, Secondary structure parameter (Si) is 
also calculated and plotted against the residue position. Typically, residues located in 
α-helices secondary structures give positive Si values while residues located in ß-
sheets give negative Si values.  
 
FIG. 9 The two protein meta-structure parameters. Residue secondary structure and 
compactness plot of the PI3-kinase p85 N-terminal SH2 domain. (PDB: 2IUG). Comparison 
of the calculated local secondary structural features (a) and compactness (b) as a function of 
residue position, and 3D protein structure (c). In the 3D structure of the SH2 domain (c) 
residues are color coded according to the meta-structure calculated local secondary structure 
results (α-helix: red; ß-sheet: blue; loosely define structure: black). (Figure is adapted from 
Konrat13). 
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1.5. Protein Structure elucidation 
Many techniques are adopted to study different aspects of proteins structure, 
but two techniques allow a resolution at the level of distinguishing individual 
atoms: X-ray crystallography and Nuclear Magnetic Resonance technique (NMR). 
Early in the 20th century, X-ray crystallography has been applied to determine the 
structure of organic and inorganic crystals. The start was with the explication of the 
structure of salt crystal, which for example allowed Linus Pauling to study atomic 
distances from which he developed his theory of the chemical bond. Based on the data 
acquired from salt crystals, Pauling introduced the hypothesis of the alpha helical and 
beta strand secondary structures15. Both of which have been confirmed by X-ray 
crystallographic analysis for the first time exploiting crystals of myoglobin in the 
early 60ies by Kendrew and co-workers16. 
Loose protein structure parts represent a challenge for the X-ray technique. The 
introduction of nuclear magnetic resonance techniques; NMR, can be used to 
overcome this problem. In contrast to protein crystals, which are crucial for X-ray 
diffraction, liquid-state NMR can be used to detect structure and dynamic of protein 
solution. Hence, these flexible structures could be resolved successfully. On the other 
hand, NMR has the problem of size limitation as large proteins are being considered a 
challenge for NMR due to fast relaxation rates.  
Moreover, with the technique of cryo-electron microscopy (a technique in which 
sample is spread as a thin film and frozen), complexes with resolution as small as 5-
10Å can be detected. One of the main advantages of this technique is that the sample 
isn’t stained or fixed in anyway which means that the protein is visualized in its native 
form in contrast to X-ray technique in which the sample is fixed in the form of crystal. 
1.5.1. X-ray crystallography 
X-ray crystallography visualizes the pattern of diffraction of X-rays that are 
shot through the crystal. The recorded diffraction pattern is a result of the interaction 
between X-rays and the electrons in the different atoms. The crystal works as an 
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amplifier because of the crystal lattice, which is packed with thousands of molecules 
and gives a unique diffraction pattern that is used to extract information about the 
structure. 
Growth of protein crystal sometimes is a tricky process; there’s no definite rule for 
the conditions at which the protein can crystallize but the whole process depends on 
trial and error, then some optimization. Polyethylene glycol is a widely used 
precipitant in the crystallization because of its efficiency and weak denaturation 
properties.     
Noteworthy, membrane proteins always tend to precipitate out of the solution due to 
unfavored interaction and this’s considered as a challenge for the crystallography 
technique. To overcome this and keep them soluble in aqueous solution, addition of 
detergents to membrane proteins is required, but on the other hand, addition of these 
detergents could interfere with the normal arrangement of the protein complex 
resulting in unexpected diffraction pattern.  
The diffraction pattern can be converted into a 3D structure by creating an electron 
density map. The mathematical formula to do this is called Fourier transformation of 
the structural factor Fhkl. The phase problem in X-ray technique is considered as an 
obstacle because the location of the electrons can’t be extracted from the diffraction 
pattern.  
The three approaches that are used for phase solving include the following: 
a- Multi-wavelength anomalous dispersion (MAD) 
Elements absorb X-ray as well as emitting them, but this absorption drops sharply 
at λ just below their characteristic emission wavelength. This sudden change in 
absorption as function of λ is called absorption edge. The absorption edge for light 
atoms as C, H or O isn’t near the wavelength used in normal X-ray wavelengths, 
hence, they all scatter normally. While in case of heavy atoms they scatter 
anomalously in this wavelength range used. As a result, phase delay is observed. For 
example, a heavy-atom derivative of methionine called Selenomethionine can be 
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incorporated into the protein structure via the use of selective media during protein 
expression. Anomalous diffraction is then recorded at a synchrotron facility. 
b- Multiple Isomorphous replacement (MIR) 
In this techniques the crystals are soaked in a heavy atom but with one condition 
that addition of this heavy atom doesn’t change more than 1% of the unit cell. 
Afterwards, Patterson difference map between native and heavy atom containing 
crystal reveals the location of the heavy atom and hence we can get the amplitude and 
phase. It’s noteworthy that these procedures should be done with 2 different 
isomorphous derivatives otherwise we could have two possibilities for the phase. 
c- Molecular replacement (MR) 
Herein, the phase from structural factors of a known similar structure is used as 
initial estimation of the phase of our new protein. Similarity between the reference 
protein and the new one should be not less than 25%.   
Protein initial models have to be refined. This is often accomplished by comparing the 
experimental data with the calculated data. The difference between the experimental 
structure and the calculated one is given as R-factor. R-factor is a measure of the 
difference between the calculated and observed structural factors of the built model 
and it’s used to validate the model.  
1.5.2. Nuclear magnetic resonance (NMR) 
NMR provides a highly sensitive way to detect protein structure. It differs 
from X-ray in that it measures mainly distances between atomic nuclei (not electron 
density). With NMR, a strong, high frequency magnetic field affects atomic nuclei 
(spins) that have magnetic spin (1H, 13C, or 15N). As a result of applying this strong 
magnetic field, some spins start to precess aligned with the magnetic field (α) and 
others aligned against the field (β). The difference between the populations of these 
two states is what creates Z-magnetization (Boltzmann equilibrium magnetization). 
Radiofrequency is then applied to take this magnetization to the transverse plane 
where the magnetization starts to resonate at certain frequency, which creates an 
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oscillatory current that is detected as time domain and then it’s fourier transformed 
into a frequency domain. The distance and type of neighboring nuclei determines the 
resonance frequency of the stimulated atomic nuclei. This dependence on next 
neighbors is parameterized by chemical shift and is considered as a parameter for the 
chemical environment of each spin. Different sets of NMR experiments have been 
designed and used starting from 1D to 6D experiments, which use the network 
connection between different nuclei to transfer magnetization via bond or via space. 
NMR can also be used as a powerful technique for detection and quantification of 
protein-ligand interaction; this will be discussed in details through different parts in 
this thesis. 
The following advantages make NMR spectroscopy a method of choice for 
biological macromolecules: 
- Protons are the most abundant spins in the protein structure.  
- It's possible to label carbon and nitrogen atoms of the protein to do multidimensional 
NMR. 
- NMR gives an idea about the dynamic of the protein, which is not the case on using 
x-ray crystallography. 
The limiting criterion in protein NMR is the size of the protein. Currently, the size 
limit for proteins size eligible for solution NMR is 40 KDa. 
In addition, although liquid-state NMR doesn’t require having the protein in ordered 
crystal lattice form, it’s demanding in the sense that it needs high concentrations of 
soluble protein (hence, NMR-derived structures are called solution structures)   
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1.6. Protein-ligand interaction 
Protein-ligand interaction is a key process required to perform diverse of 
biological functions, hence, interfering with this interaction is a therapeutic concept. 
Ligand is a small molecule that binds a biomolecule as protein to perform a specific 
biological function. The binding occurs by intermolecular forces, for 
example, hydrogen bonds, ionic bonds and van der Waals forces, this association is 
usually reversible (dissociation). Association between ligand and the biomolecule 
leads sometimes to conformational changes and this leads to modification of the 
function of the biomolecule. The interaction between a protein and a ligand is 
usually specific, so the protein can discriminate between many different molecules 
and bind only one particular molecule or one of a number of very closely related (i.e. 
chemically and structurally similar) molecules. Protein–ligand interactions range from 
weak and transient to strong and persistent, depending on the strength of the non-
covalent bonds. 
To describe the affinity between a protein and ligand, the term dissociation constant 
(KD) is used17. KD is the molar concentration of the ligand at which half of a specific 
site on the protein is occupied. The lower the KD the higher the affinity between the 
protein and the ligand. Dissociation constant can be determined by several methods, 
one of the most important techniques is isothermal titration calorimetry18. 
 
FIG. 10 Ligand binding site, which is often formed in a cleft or a pocket on the protein 
surface. Protein is shown in green while ligand is shown in magenta.  
 
Finding ligands for the targeted biomolecule can be achieved via different methods.  
Examples of known methods are:  
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1-Protein-structure-similarity clustering (PSSC): it’s used to investigate potential 
ligands for specific protein19. In this technique, proteins that share the similar 
structure rather than sequence identity are the ones of interest, and hence, it serves as 
a guiding mechanism to select natural products to target structurally similar proteins. 
The main disadvantage of this technique is that the 3D structure of the binding motif 
should be conserved for comparison, but the lack of 3D information about a lot of 
proteins that have pharmacological interest stands as a limitation for using this 
method.  
2- Recently, meta-structure approach can be used to design a library of different 
fragments based on the similarity between the targeted protein and other proteins in 
the database13. The meta-structure parameters are used as a powerful comparison tool 
between proteins based on sequence. Only by knowing the sequence of the protein, 
it's possible to detect the meta-structure parameters, which are then aligned with other 
proteins in the database to predict structure and possible ligands by doing protein-
Meta-Structure similarity clustering (PMSSC). As it depends only on the sequence, so 
it can be used even for proteins that have unknown 3D structure and of biological 
relevance. Figure 11 shows the difference between the use of PSSC and PMSSC for 
finding possible protein ligands.  
In PSSC, conserving of structural motifs in the ligand sensing region. It’s 
limited because of the limited information available for therapeutically 
relevant protein targets 
In PMSSC, meta-structre similarities in the ligand binding sites!
 
FIG. 11 Meta-structure alignment as a powerful tool to detect possible ligands from drug data 
bank in comparison t  PSSC. (Figure is adapted from Konrat13). 
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1.7. Fragment Based Drug Design. 
The indispensible starting point of FBDD is the identification of small 
molecule that are weak binders in the size range of 100− 300 Da and characterized by 
being drug-like20. In comparison, High-throughput screening (HTS) in which 
diversity of compounds are distributed well-plates where the targeted protein is added 
and the interaction is then measured using different methods like measuring the 
reflectivity21, the HTS screen can contain up to 105 compounds and this covers only 
small fraction of possible small molecules. On top of that, HTS sometimes fails to 
provide compounds of biological relevance in drug industry because the compounds 
tested are of non-drug nature and this makes them not-applicable in the 
pharmaceutical industry20. 
 
 
FIG.12 The main principles for fragment based drug design, which include library design, a 
method to test the binding of the fragments, and then the development into larger compounds 
using growing or linking. 
 
The fragment library usually based on selection of a list of available chemical 
compounds with exclusion of toxic or reactive compounds22.  More focused libraries 
also can be designed taking in account substructure of know pharmacologically active 
compounds23. The challenging point in FBDD is that the fragments tested are usually 
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of weak binding to the tested biomolecule, hence a sensitive method are needed to test 
the binding. These fragments are then developed into larger compounds either via 
merging/linking fragments together or via growing the fragments to enhance the 
binding. In linking, two or more fragments that are known to be binding to different 
sites on the target are linked together with a linker to have the product of the KD of the 
linked fragments. On the other hand, growing means to augment the binding via 
addition of functional groups. 
There are wide variety of techniques that can be used in order to measure binding 
between the targeted protein and the selected fragments like NMR and surface 
plasmon resonance24. Indeed, detection of the binding between these fragments and 
the proteins is challenging due to the weak binding  (KD usually in the mM range). 
Therefore, NMR provides a unique technique due to its high sensitivity and reliability 
in this area. The first published fragment based lead discovery by NMR was described 
by Abbott group25 and the binding was detected by the perturbation of the HSQC 
spectrum of labeled protein upon addition of the ligands. Different NMR techniques 
can be used to elucidate the binding events; some of them have been used in this 
investigation and will be discussed in details.  
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1.8. ß-Catenin & TCF4 
1.8.1. Structure and function of Catenins 
The word catenin originated from the Latin word catena which has the 
meaning of a chain26. With the exception of structurally unrelated α-Catenin27, all 
human catenin family members contain a central Armadillo repeat domain that 
contains between 9 to 12 repeats (each repeat is 3 α-helices formed of about 40 amino 
acids)28. This Armadillo repeat region folds to produce a super-helix of helices that 
bears a positively charged groove which is indispensable for binding29. The catenin 
proteins family is classified into three subfamilies depending on their function30. 
 
FIG. 13 Classification of catenin into three subfamilies. (Figure is adapted from McCrea and 
Gu31). 
 
ß-Catenin is the most relevant member in catenin family31. It consists of N-terminal 
domain (NTD), armadillo repeat domain and C-terminal domain (CTD). The 
armadillo repeat region consists of 12 repeats and it's the main region involved in 
protein binding while the N-terminal domain is essential for the process of 
proteosomal degradation of the protein, and C-terminal domain contributes to gene 
transactivation. 
 
FIG. 14 Structure of full-length ß-Catenin. (Figure ia adapted from Mosimann et al.32). 
 
ß-Catenin is involved mainly in two functions: 
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a- Binding to cadherin at cell-cell junctions (where ß-Catenin binds with E-
cadherin and α-Catenin to link them to the actin cytoskeleton)33. 
b- It's the main component in canonical Wnt signaling pathway 
1.8.2.  Canonical Wnt signaling 
The Wnt family of proteins consists of 19 known human members34,  and of 
size 40 KDa35. These secreted Wnt are modified by glycosylation and can bind to 
Frizzled family receptors on the plasma membrane. Two domains on Wnts bind to 
Frizzled receptors and one of them contains palmitoleic acid lipid which projects 
inside the pocket of the receptor36. 
Interactions of Wnts with their receptors are associated with three signaling pathways; 
canonical Wnt/ß-Catenin pathway, non-canonical Wnt/Ca+ pathway and planar cell 
polarity pathway. In this research we are concerned mainly about the canonical 
pathway in which ß-Catenin is playing the crucial rule. 
In the absence of Wnt ligands, ß-Catenin in the cell cytoplasm is degraded by 
phosphorylation of the serine and threonine amino acids of the N-terminal by the 
destruction protein complex37. This complex consists of five different proteins like the 
tumor suppressor protein APC; an active serine-threonine kinase. On the other hand, 
in presence of Wnt ligands, they bind to frizzled receptor on the cell membrane and 
this results in recruiting the destructive phosphorylation complex. Subsequently, ß-
Catenin escapes degradation and is translocated into the nucleus where it interacts 
with the DNA-binding T-cell factor/ lymphoid enhancer factor (TCF4/LEF) family 
proteins, replacing TCF4-bound corepressors leading to the conversion of TCF into a 
transcriptional activator of Wnt target genes38 such as cyclin D1, c-Myc, survivin and 
COX-2. This Canonical pathway is involved in different cellular behavior such as 
embryogenesis, growth, cell division and apoptosis32. 
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FIG. 15 Canonical Wnt signaling pathway. On the left, in absence of Wnt ligands. On the 
right, in presence of the Wnt ligands. (Figure is adapted from Mosimann et al.32). 
 
Noteworthy, upon mutation of ß-Catenin (N-terminal serines or threonines amino 
acids)39 or any of the phosphorylation destruction complex members, ß-Catenin 
escapes from degradation and accumulates in the cell. These mutations impair the 
regulation of ß-Catenin levels and affect mainly the tissues that depend on Wnt for 
repair. This overexpression of ß-Catenin lead to continuous formation of complex 
with TCF4, which is associated with number of human tumors including colorectal, 
lung, breast, cervical, skin and hepatic tumors40. Thus, ß-Catenin is considered as a 
potential oncogene. From this perspective, blocking of the Wnt signaling pathway as 
possible antitumor therapeutic intervention could be achieved via targeting the 
complex between TCF4 and ß-Catenin. 
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FIG.16 Structure of the complex between armadillo repeat region of ß-Catenin (green) and 
TCF4 (red). TCF4 residues 13-25 runs as extended region in the twist formed by the 
armadillo repeat region. While residues 40-50 of TCF4 runs as α-helix in the shallow groove 
formed by repeats 3,4, and 5 of ß-Catenin. (Protein Databank Entry: 1JPW). 
 
1.8.3. ß-Catenin/TCF4 complex as antitumor target 
1.8.3.1. Disruption of ß-Catenin/TCF4 as a new antitumor target 
The Wnt/ß-Ctenin pathway is linked to cancer via the activation of TCF4/ß-
Catenin activated genes. Abnormal activation of the Wnt/ß-Catenin pathway is a 
frequent early event in intestinal epithelial cells during the development of colon 
cancer41, which promotes the expression of Wnt/ß-Catenin responsive genes, 
including cyclin D1, myc, and PPAR-δ, which play crucial roles in colorectal 
tumors42. 
Based on that, disruption of ß-Catenin/TCF4 complex has been considered a 
prominent target to design new antitumor drugs43. It was shown that disruption of 
such complex results in down regulation of the oncogene c-myc, which was shown to 
be extensively expressed in colorectal cancer44. 
Recently, several Wnt inhibitors were identified in high throughput screening that 
target the upstream signaling of ß-Catenin in order to promote its degradation45.  
 
1.8.3.2. Literature survey on antitumor compounds related to ß-Catenin 
Natural products found in food are potentially ideal therapeutic agents for 
cancer. Resveratrol (1) is a phytoalexin produced in plants particularly in red grapes 
and blueberries46. Resveratrol has been suggested to induce ß-Catenin degradation 
and inhibits its nuclear localization in colorectal cancer cells47. 
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Zhang et al48 reported the synthesis and evaluation of novel resveratrol analogues as 
anticancer that work against Wnt signaling. It was proved that (E)-4-(2,6-
difluorostyryl)-N,N-dimethylaniline (2) is highly active as antitumor agent targeting 
Wnt pathway. 
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In addition, Lepourcelet et al43 screened about 7000 natural low molecular weight 
compounds at 10µM concentrations for their ability to disrupt the ß-Catenin/TCF4 
complex. Six compounds isolated from microbial origin showed reproducible dose-
dependent inhibition of ß-Catenin/TCF4 interaction. These compounds showed 
diverse structural properties although they share the polyhydroxylated scaffolds. 
These compounds are; PKF115-584 (3), CGP049090 (4) and PKF222-815 (5) which 
are isolated from fungal organisms, whereas PKF118 (6), PKF118-310 (7) and 
ZTM000990 (8) and they are isolated from Actinomycete strains. 
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1.8.3.3. Drugs that target the Wnt target genes 
Amongst the Wnt target genes are PPAR-ɣ and COX-2, both of them have 
been proved to play a rule in the development of colorectal tumors. Both of these 
genes are inhibited by non-steroidal antiinflammatory drugs (NSAIDs), which have 
been shown in turn to inhibit colon cancer. COX-2 produces eicosanoids (such as 
prostaglandins) from arachidonic acid and these eicosanoids are themselves PPAR-ɣ 
ligands that stimulate transcription. PPAR-ɣ is upregulated in early carcinogenesis by 
the hyper-activity of TCF4/ß-Catenin complex34. Treatment of mutant mice with the 
selective COX-2 inhibitor; MF tricyclic (9) was shown to reduce polyp number49 and 
the treatment of patients with familial adenomatous polyposis with COX-2 inhibitor; 
celecoxib (10) showed significant decrease in the number of colorectal polyps50. Also 
levels of nuclear ß-Catenin in patients with adenomatous polyposis were reduced 
significantly when treated with the NSAID sulindac (11) for 6 months. In spite of this, 
the treatment with the selective COX-2 inhibitors is still controversial due to the 
possibilities of developing blood clots and strokes51.  
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2.1. NMR screening in drug discovery: 
 In fragment based drug design (FBDD), different fragments are tested for 
binding to the target biomolecule. As mentioned before, the problem with this method 
is the weak affinity of these fragments, which limits other conventional methods from 
detecting this. Therefore, NMR serves here as a sensitive technique, that can be used 
to demonstrate binding of those low affinities fragments.  
Two main methods are used for protein-ligand binding investigation using NMR; 
either observing target resonance or ligand resonance. 
2.1.1. Ligand resonance observing method 
Different sets of experiments have been designed in order to see the protein-
ligand interaction like saturation transfer difference NMR, 19F-NMR, water-LOGSY 
and NOE-ROE experiments. Usually these methods provide the advantage of having 
short time measurement experiments in addition to the absence of limitation of the 
macromolecule size. The main limitation of this method is the lack of ability to detect 
tight binding ligands as the slow dissociation rate inhibits the transfer of the 
magnetization on the small bound fraction to the bulk unbound one which is the one 
that is recorded in this kind of experiments52.  
In order to overcome the drawback of high affinity limitation, different approaches 
have been adopted such as reporter screening53 and spin labeling54. 
2.1.2. Target resonance observing method 
Herein, the changes of the macromolecule chemical shift (e.g. protein) are 
observed upon the binding to the ligand. One of the main advantages of this method is 
the possibility to detect the binding site on the protein if the assignment of the target 
is available. On the other hand, the biggest obstacle in this process is the size limit of 
the macromolecules which is usually limited to 40-50 KDa55, as at larger size, the 
spectrum usually suffer from faster relaxation properties which lead in turn to line 
broadening. Moreover, this method is limited by the need to prepare expensive 
labeled sampled  (e.g. 15N and/or 13C labeled). 
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2.2. NMR experiments adopted during this investigation: 
2.2.1. Protein-Ligand Binding elucidation NMR experiments: 
2.2.1.1. 1D 1H -Saturation Transfer Difference NMR: (STD)56 
 Saturation transfer difference approach can provide a detailed picture on the 
interaction between ligands and protein targets, and also to detect possible epitopes. 
The STD experiment can also be applied as screening technique in the dynamic 
combinatorial libraries to identify high-affinity ligands. The method requires only 
small amount of the unlabeled target protein and a 50-100-fold excess of ligand(s). 
In this technique, RF irradiation of the protein spins at a resonance where no ligand 
signals are present is done; this is achievable because of the unique chemical 
environment of the protein and because of the huge line width of the protein signal in 
comparison to sharp peaks of the small ligands, so the protein spins have significant 
signal intensity even in segments outside the spectral window of low-molecular-
weight ligands as in the negative ppm region (less than zero ppm) or above 10 ppm. 
This selective protein irradiation leads to saturation of the entire protein via spin 
diffusion. If the ligand binds the protein, saturation will spread onto the ligand. So the 
ligand spins that are closer to the protein receive more intermolecular NOE. As a 
result, intensity of the ligand signal is attenuated. Subtraction of resulting spectrum 
from the reference 1D 1H-spectrum (where the RF irradiation is done so far from the 
area of interest) yields the positive 1D 1H-STD spectrum, which contain only signals 
from the binding ligand (s). If the ligand is not binding, the resulting subtraction 
spectrum will be just a zero 1H-STD spectrum. The experiment is repeated in the 
absence of the protein to be sure that a zero 1H-STD spectrum is produced (negative 
control experiment). 
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FIG. 17 Schematic representation of the saturation transfer difference NMR experiment. The 
degree of saturation of the ligand protons is represented via the size of the proton in the 
figure. The larger the proton size in the figure means the closer it’s to the protein surface and 
the more amount of magnetization it gets. (Figure is adapted from Mayer and Meyer56). 
 
2.2.1.2. 19F-NMR screening 
19F atom has unique chemical properties that attracted great attention in the 
pharmaceutical industry. It can affect the physico-chemical properties of the 
molecule, which is translated into better penetration into the membrane for example. 
In addition, C-F bond is 7 Kcal stronger than the C-H bond and that makes it more 
resistant to enzymatic attack. 19F-NMR ligand screening offers unique advantages; a) 
high sensitivity and the natural abundance of the 19F nucleus, b) no interference from 
protonated buffers or reagents, c) absence of overlap because of the wide dispersion 
of the peaks, d) the 19F transverse relaxation rate R2 in bound state is highly sensitive 
to binding due to high exchange contribution57. This R2 sensitivity to binding is 
directly reflected on the peak width. Hence, when a fluorinated ligand binds to a 
protein, a broadening of the 19F-peaks involved in the binding site is observed. In 
addition, competitive-based fluorine screening has been described as a tool for 
detection of binding constant. In this technique, the fluorinated ligand acts as a (spy) 
molecule that could be displaced by non-fluorinated ligand, which gives the 
advantage of avoiding the overlap between the spy, and the non-fluorinated ligand. 
 
Theoretical   
 
34  
 
FIG. 18 19F-NMR of fluorinated ligand (s) in presence and in absence of the binding protein 
showing broadening of the peak upon binding in comparison to the control sample (c). (The 
figure is adapted from Dalvit57). 
 
2.2.1.3. 2D-homonuclear 1H-1H NOESY 
NOESY is very illuminating NMR experiment in terms of structure and it 
gives a clear idea about the neighborhood between protons can be extracted. The main 
building block of NOE experiment consists of 90˚ pulse to label the protons with their 
chemical shifts, followed by evolution time. Afterwards, another 90˚ pulse is applied 
which takes the magnetization to the z-axis, followed by a mixing time delay (τm) 
during which the perturbed spins return to equilibrium via reshuffling of the spins 
population and hence transfer the magnetization to other spins in the system via cross 
relaxation (σ) in distance range 5 A˚. Finally, another 90˚ pulse is applied to bring the 
magnetization back to the transverse plane, and followed by detection58.  
 
 
FIG. 19 The building block of NOE experiment pulse sequence. 
 
In the observed spectrum, we see mainly two types of peaks; the diagonal peaks 
which appear at offset (Ω1, Ω1) of spin 1, and cross peaks, which appear at (Ω1, Ω2) 
for spin 1 and 2 respectively. The cross peaks are the ones that carry the information 
about possible interaction between spin 1 and 2. The intensity of these peaks at short 
mixing time is (σ τm). In case of fast tumbling molecules, the cross relaxation rate is 
positive so we see negative peak, while for large slowly tumbling molecules, σ is 
negative and the cross peaks appear with positive sign (same as the diagonal peaks). 
The change of sign of the NOE cross relaxation rate arises from the fact that σ=W2-
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W0 where W2 is the probability to have double quantum transition, while W0 is the 
probability to have zero quantum transition. For small molecules, W2 is larger than 
W0 which makes the sign of the cross relaxation rate positive, while for large 
molecules, W2 starts to decline while W0 continues to linearly increase resulting in 
negative sign for σ. 
 
FIG. 20 2D homonuclear 1H-1H NOE showing diagonal and cross peaks signs. 
 
The cross relaxation rate is proportional to the reciprocal of distance between the two 
spin (r-6), hence usually it’s observed if the distance between the 2 spins is in the 
range of 5 A˚. In addition, the cross peak intensity is dependent on the mixing time, 
where the magnetization starts to build up, followed by a maximum and then the 
magnetization starts to decay. Therefore, one has to be careful with choosing the right 
mixing time depending on what kind of NOE wanted to be observed; in case of spin 
diffusion, longer mixing time should be chosen, as the intensity is now dependent on 
quadratic term (σ2 τm 2/2).  
 
Measuring 2D 1H-1H NOE at different mixing time for a small ligand in presence of 
protein can provide an efficient tool to observe change of the intensity of the cross 
peaks and to map the ligand protons that are imbedded in the binding site. From the 
NOE build up curves, it’s possible to see spin diffusion effect on some protons of the 
ligand which can be translated into binding between these protons and the protein. 
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2.2.1.4. Cross relaxation during Adiabatic Fast Passage59. 
The nuclear overhauser effect (NOESY) is an information-rich NMR 
technique for structure determination studies and it refers to the longitudinal cross 
relaxation. In addition, it’s also proved that Rotating Frame overhauser spectroscopy 
(ROESY) can provide unique information about dynamics of proteins60. ROESY 
refers to the transverse cross relaxation. 
In this method, the NMR experiment measures homonuclear (1H-1H) cross relaxation 
rates (NOEs and ROEs) during adiabatic past passage (AFP) which is convenient 
method for the examination of protein ligand binding. 
Unlike conventional AFP methods, the RF field is not small but of comparable 
strength to the sweep frequency (γB1≈∆ω) and so leading to significant contribution 
of transverse relaxation to the effective spin lock relaxation rate.  
 
FIG. 21 The effect of the strength of the applied AFP on the amount of the transverse 
magnetization. The figure shows that increasing γB1 increases the amount the net amount of 
transverse magnetization during the sweep. In the middle of the sweep, the transverse 
magnetization reaches the on-resonance condition. (Figure is adapted from Konrat and 
Tollinger61). 
 
The pulse scheme for this experiment is a conventional NOESY in which the AFP 
that has parabolic phase shift in order to create a time dependent offset, replaces the 
original longitudinal mixing period. Therefore, the effective relaxation rate for two 
spins i and j is 
σijeff= σNOEcos θicos θj + σROE sinθi sinθj 
Where θ is the angle between the offset and the effective fields, σNOE is the NOE cross 
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relaxation and σROE is the ROE cross relaxation. 
 
 
FIG. 22 Frame of the Adiabatic spin lock shows the following: offset Δw(t), r.f. field w1(t), 
effective field weff(t) and the angle θ(t) between offset and the effective field. (Figure is 
adapted from Auer et al.59). 
 
For small molecules like ligands, both NOE and ROE enhancements are the same 
(+50%) and the spin lock relaxation rate is independent on the strength of the applied 
AFP strength during mixing time. For large molecules, NOE and ROE enhancements 
aren’t the same as they have different value and different sign (NOE becomes 
negative -100%, while ROE remains positive and has higher value +200%). As a 
result, for large molecules, the enhancement will be dependent on the AFP strength. 
As the strength of the AFP increases, the relaxation shifts from NOE to ROE regime. 
During this moving from the NOE to ROE, there will be a zero crossing. For rigid 
macromolecules with no internal mobility, the zero crossing happens at angle θ = 
35.5˚. 
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FIG. 23 NOE and ROE enhancement (η is the enhancement; ω2Γc2 is a parameter of size 
based on correlation time and the larmor frequency). (Figure is adapted from Auer et al.59). 
 
It’s noteworthy that this zero crossing angle can be less than 35.5˚ because of high 
internal mobility (order parameter S2 > 0.5), or it can be larger in case of spin 
diffusion.  
 
2.2.2. Protein Reductive Methylation 
 Protein reductive methylation was first introduced in 1968 by Means and 
Feeny62. It’s used to enhance the crystallization. Some proteins are resistant for 
crystallization because of the flexible nature of the surface residues. Hence, lysine 
residues, which are characterized by polar, flexible and long side chain, can be 
localized in order crystal lattice formation. Therefore, reductive methylation of the 
lysine side chain was found to have the ability to increase the hydrophobic surface of 
the protein in aqueous media, which favors the protein-protein hydrophobic 
interaction, and hence better packing of the protein in the crystal lattice. This in turn is 
reflected into better crystallization conditions63.  
Synthesis of selectively lysine-methylated protein can be recruited by NMR to have a 
sensitive method for detection of protein conformational changes induced by small 
molecules binding and protein-protein interaction. Methyl groups provide a wonderful 
probe for NMR due to; a) high sensitivity as it has 3-fold symmetry, b) high side 
chain mobility which means higher relaxation time, c) using selective labeling methyl 
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groups allow the labeling of unlabeled proteins from all kind of sources. Methylation 
doesn't significantly perturb protein structure, it retains the positive charge64 and 
doesn't induce protein-protein interactions65. On top of that, reductive methylation of 
large proteins provides favorable relaxation properties because of the reduced order 
parameter (S2) of the lysine side chain, which can be in turn recruited for proteins like 
ß-Catenin that are problematic for conventional NMR measurements. So, 13C methyl 
groups added to lysine side chain can be detected with higher sensitivity than those on 
aliphatic amino acids in the 13C labeled proteins. 
In this technique, two 13C-methyl groups are introduced on each lysine amino acid in 
a non-labeled protein sample66. 
To achieve this selective methylation of the lysine amino acids, 13C-labeled 
formaldehyde is added to the protein. The formed imine is subsequently reduced in 
presence of borane ammonium complex to give secondary amine that carries one 13C-
labelled methyl group. Afterwards, excess of 13C-labelled Formaldehyde and reducing 
agent is added to the protein resulting in formation of tertiary amine carrying two 13C-
labelled methyl groups for each lysine residue. 
 
FIG. 24 Reductive methylation reaction showing the two steps addition of two methyl groups 
to an ɛ-amino group of a lysine residue or the N-terminal amino group through the formation 
of Schiff’s base intermediate. (a) Initial step of the reaction to form monomethylated lysine. 
(b) In the presence of sufficient formaldehyde, the reaction proceeds to give the di-methylated 
lysine derivatives. 
 
In this investigation, synthesis of 13C-methylated lysines of ß-Catenin was adopted by 
using the previously described method64 to yield a tertiary amine (di-methylated 
derivative). 
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1H-13C 2D-HSQC NMR spectra were recorded for the newly synthesized methylated 
ß-Catenin alone, in the presence of its binding partner; TCF4 and with the detected 
binding ligand; sodium 2-phenoxybenzoate. From this experiment it was possible to 
confirm the similarity in the binding site between TCF4 and sodium 2-
phenoxybenzoate on the ß-Catenin. 
 
 
2.2.3. Protein assignment NMR experiments: 
“The figures of magnetization transfer for this section are taken from the site 
http://www.protein-nmr.org.uk/spectra.html developed by Biochemistry Department, 
University of Oxford South Parks Road Oxford OX1 3QU, UK.” 
 
In 2D and 3D NMR assignment experiments, the main building block is INEPT 
(insensitive nuclei enhanced by polarization transfer). In INEPT, the magnetization is 
transferred from the highly sensitive nuclei (usually 1H) with the highest 
gyromagnetic ratio (hence, highest Boltzman equilibrium magnetization) to the less 
sensitive one (like 14N or 13C). Then using reverse INEPT, the magnetization can be 
transferred back to the sensitive nuclei for detection.  
 
FIG. 25 Pulse sequence of INEPT experiment done on two spins (I and S) where I is the most 
sensitive nuclei and S is the less sensitive one. 
 
In figure 25, the pulse sequence of INEPT is shown. Spin I is the spin with the highest 
sensitivity (e.g. 1H) while spin S is the less sensitive one (e.g. 13C or 15N). At point A, 
after a 90˚ pulse on spin I, the operator will be Iy. During the delay τ, evolution of 
scalar coupling between spins I and S, so the operator will be Iy cos 
(πJISτ)+2IxSzsin(πJISτ). At point B, after applying 180˙ pulses on both spins the 
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operator will be -Iy cos (πJISτ)-2IxSzsin(πJISτ). At point C, the operator will be –Iy cos 
(πJIS2τ) -2IxSz sin (πJIS2τ). So if 2τ=1/2JIS, the only remaining term will be a pure 
antiphase magnetization -2IxSz sin (πJIS2τ). At point D, after applying 90˚ pulses on 
both spins, the operator will be -2IzSy, which means that we started with transverse 
magnetization on spin I and we ended with transverse magnetization on spin S 
(coherence transfer).  
 
2.2.3.1. 2D 1H-15N HSQC (heteronuclear single quantum coherence 
spectrum): 
This is the most standard and initial NMR experiment and creates H-N 
correlations (via 1 bond scalar coupling). It’s considered as the fingerprint for the 
proteins and requires 15N labeled protein. 
The main regions that are observable in the spectrum include the following: 
a- Backbone amide groups 
b- Tryptophan side-chain Nε-Hε (appears downfield) 
c- Aspargine/Glutamine side-chain Nδ-Hδ2/Nε-Hε2 groups respectively.  
d- The Arginine Nε-Hε (appears as folded peak with opposite sign to the 
other peaks because the Nε chemical shift of arginine is outside the 
spectral width recorded) 
Mostly in this experiment, it starts with the equilibrium magnetization on 1H rather 
than on the heteronucleus because proton has higher Boltzmann equilibrium 
magnetization, which enhances the sensitivity as mentioned before. In addition, 
proton magnetization returns to its equilibrium value faster than the one of other 
heteronuclei so the time needed for waiting between scans is less and hence reduces 
the experiment time.  
The pulse sequence for HSQC experiment starts mainly with INEPT to transfer 
magnetization from the 1H to 15N followed by evolution time (t1) which allows to 
label the spins of 15N spins with their chemical shifts, followed by back INEPT to 
transfer the magnetization back to 1H for detection (t2).  
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FIG. 26 Pulse sequence of HSQC experiment done on two spins (I and S) where I is the most 
sensitive nuclei and S is the less sensitive one. 
 
It’s also noteworthy to mention that there’s a short version of this experiment called 
sofast in which only 30˚ or 40˚ soft pulses instead of 90˚ pulse are applied to 
selectively excite backbone amide protons spins, hence, this reduces the time needed 
for the bulk equilibrium magnetization to build up again and this in turn means more 
time saving between scans.  
 
FIG. 27 Magnetization transfer in 2D 1H-15N HSQC. (Figure is adapted from site 
http://www.protein-nmr.org.uk/spectra.html). 
2.2.3.2. 3D 1H-15N- 13C HNCA67: 
Here the magnetization is passed from 1H to 15N on the backbone and then 
via the N-Cα scalar coupling to the 13Cα and then back again to 15N and 1H 
hydrogen for detection. The chemical shift is evolved for 1HN, 15NH and 13Cα, 
resulting in a 3-dimensional spectrum. 2 Peaks of both Cαs (Cαi and Cαi-1) are visible 
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in the spectrum for each NH because the amide nitrogen is coupled with both Cαs. 
The peaks of Cαi appear more intense in comparison to the ones of Cαi-1 because of 
the higher coupling to the directly attached Cα.  
 
FIG. 28 Magnetization transfer in 3D 1H-15N-13C HNCA. (Figure is adapted from site 
http://www.protein-nmr.org.uk/spectra.html). 
 
2.2.3.3. 3D 1H-15N- 13C HN(co)CA68: 
This experiment is homologous to the HNCA with one modification that the 
magnetization is passed from 1H to 15N and then to 13CO. From here it is transferred 
to 13Cα. The chemical shift is evolved only for the Cα but not for the CO. This results 
in a spectrum, which is similar to the HNCA, but only one peak is observed for each 
NH corresponding to the Cα of the preceding residue (Cαi-1). 
 
FIG. 29 Magnetization transfer in 3D HN(CO)CA. (Figure is adapted from site 
http://www.protein-nmr.org.uk/spectra.html). 
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2.2.3.4. 3D 1H-15N- 13C HNCACB69: 
Magnetization is transferred from 1Hα and 1Hβ to 13Cα and 13Cβ, 
respectively, and then from 13Cβ to 13Cα then to 15NH and to 1HN for detection. So 
for each NH group there are two recorded Cα and Cβ peaks belonging to the i and i-1 
residues. The signal intensity for the i peaks are more than those of the i-1 because of 
the stronger scalar coupling. In This experiment, signal intensity is distributed 
between among four resonances in the 13C dimension and this makes it much less 
sensitive experiment in comparison to HNCO or HNCA. 
 
FIG. 30 Magnetization transfer in 3D HNCACB. (Figure is adapted from site 
http://www.protein-nmr.org.uk/spectra.html). 
 
2.2.3.5. 3D 1H-15N- 13C HNCO67: 
Magnetization is passed from 1H to 15N and then selectively to 13CO via the 
15NH -13CO J-coupling. Magnetization is then passed back via 15N to 1H for 
detection. Herein, we observe only one peak for each NH corresponding to the COi-1, 
but nothing is observed for the COi because the scalar coupling between 15N and 
13COi is approaching zero. 
HNCO experiment is much more sensitive in comparison to HNCA. The reduced 
sensitivity of HNCA experiment is due to: 
a- Distribution of magnetization in HNCA on two coupling partners ( Cαi and  Cαi-1). 
b- Smaller 1J coupling in HNCA 
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FIG. 31 Magnetization transfer in 3D HNCO. (Figure is adapted from site 
http://www.protein-nmr.org.uk/spectra.html). 
 
2.2.3.6. 3D 1H-15N- 13C HN(ca)CO70: 
The Magnetization is transferred from 1H to 15N and then via the N-Cα scalar 
coupling to the 13Cα. From there it is transferred to the 13CO via the 13Cα-13CO 
scalar coupling. For detection, the magnetization is moved back in the opposite 
direction till finally it reaches 1H. The chemical shift is only evolved on 1H, 15N and 
13CO. Because the amide nitrogen is coupled both to the Cα of its own residue and 
that of the preceding residue, both these transfers occur and transfer to both 13CO 
nuclei occurs. So for each NH group, two carbonyl groups are observed in the 
spectrum. But because the coupling between Ni and Cαi is stronger than that between 
Ni and Cαi-1, the Hi-Ni-COi peak generally ends up being more intense than the Hi-
Ni-COi-1 peak. 
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FIG. 32 Magnetization transfer in 3D HN(ca)CO. (Figure is adapted from site 
http://www.protein-nmr.org.uk/spectra.html). 
 
For protein assignment in this work, it starts with observing the Cα and Cβ chemical 
shifts of some amino acids in the sequence, which have characteristic values. For 
example, alanine has a unique upfield value for the Cβ around 20 ppm, while serine 
and threonine are the opposite, as they have downfield characteristic Cβ chemical 
shift around 60 and even more downfield than their Cα, on the other hand, glycine 
residue has no Cβ at all. Detecting these amino acids is a good start to connect a series 
of amino acids in the sequence using the different measured spectra. Figure 33 shows 
4 strips from HNCACB spectrum and how these strips can be connected to predict a 
chain of residues.  
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FIG. 33 Assignment of residues chain using HNCACB spectrum. 4 strips at different 15N 
chemical shifts are shown. The blue peaks are the Cβ peaks while the red ones are the Cα 
peaks. ω3 is 1H, ω2 is 13C, while ω1 is 15N.  
 
 
FIG. 34 Sample of assignment of TCF4 protein at pH=4.5 showing 3 different strips of 1H-13C 
spectra at 3 different 15N frequencies in the HNCACB spectrum and how to connect the three 
residues together. CA peaks are in orange, while CB peaks are in violet.  
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2.3. Dynamic Combinatorial Chemistry 
Dynamic combinatorial chemistry is an outstanding new approach that 
combines the library generation and screening processes71. One of the key issues in 
designing dynamic libraries is the choice of the reversible chemical reaction that can 
interconvert the library components. This reversible interconversion between the 
library components makes the library mainly governed by thermodynamics rather 
than kinetics72. Unfortunately, the reversibility of the reaction between the building 
blocks of the library puts a limitation on the type of reactions that can be used for 
such a technique. 
In addition, the second crucial point in designing a dynamic combinatorial library is 
to have the availability to do in-situ measuring of the binding between the library 
components and the target protein. The reactions that can be used for dynamic library 
shouldn’t interfere with the method used to test the binding.  
A number of such reactions have been tested, which include transacylation73, imine 
exchange74, isomerization75, thiol-disulfide exchange76 and ligand exchange in 
coordination complexes77. 
Herein, we showed that imine formation is a fast and efficient reversible reaction that 
can be used to generate systems of potential ß-Catenin inhibitors under neutral 
conditions. These systems were also subjected to direct binding analysis by saturation 
transfer difference (STD) 1D NMR spectroscopy, a rapid and efficient technique for 
protein–ligand-binding studies78, in which the optimal imine interactions with the 
biological target can be readily deduced. 
 
FIG. 35 Concept of direct STD NMR identification of ß-Catenin inhibitors from a virtual 
dynamic imine system. (The figure is adapted from Caraballo et al.79). 
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The addition of 2 amines to 2 aldehydes through nucleophilic addition was done in 
the NMR tube in absence and in presence of the targeted protein ß-Catenin resulting 
in the synthesis of four new imines. 1H STD NMR was performed for each separate 
component of the library and for the library components together by tracking the 
proton signal of formyl and imine groups.  
This combination of dynamic system formation with STD NMR spectroscopy, 
resolving complex systems by the identification of the best ligands, can be easily 
expanded to accommodate a wider variety of compounds, resulting in efficient and 
rapid mapping of protein inhibitory potentials. 
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2.4. Isothermal titration calorimetry (ITC) 
ITC is a non-destructive technique that directly measures the change in 
enthalpy (ΔH), stoichiometry (n) and the dissociation constant (KD) for bimolecular 
binding interaction. ITC can also is used to give complete thermodynamic and kinetic 
profile of a certain reaction in a one or two-hours experiment80. In addition, the 
samples can be recovered to be used for other measurements since the technique isn’t 
invasive and doesn’t require temperature elevation. However, the experiment must be 
well-designed and certain information like reactants concentrations need to be 
understood81. It’s also very crucial to consider the sample preparation, the experiment 
design and the instrument used82. 
A typical ITC instrument consists of two identical cells made of an inert material that 
is highly efficient thermal conducting; one is a reference containing water, buffer or 
solvent to provide a reference of comparable heat capacity. The other cell, a sample 
cell which typically contains 0.5-1.5 ml of the protein sample in which ligand is 
injected at a fixed temperature in the range 5-60°C. Ligand which is in the syringe 
and titrated into the sample cell should have the same buffer system and salt 
conditions as the protein. The main drawback about using ITC is that it’s not up for 
large scale analysis so it can’t be used for example to investigate binding of libraries. 
 
 
FIG. 36 Schematic presentation of ITC instrument. (Figure adapted from Zhou et al.83). 
 
Upon making injection of ligand, heat is either released or consumed (the process is 
endothermic or exothermic). These small heat effects are detected as the thermal 
power (µcal/s) needed to compensate for the ligand induced heat effect and to put the 
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cell back into thermal equilibrium. Initial injection of ligand into the cell gives large 
heats since almost all injected ligand binds to the targeted protein. However, as the 
titration continues, binding sites become more and more occupied and the amount of 
the heat per injection declines. Eventually, all the binding sites are filled (saturation) 
and the heat change corresponds only to dilution heats. Sample of raw data obtained 
from ITC is shown in figure 37. 
 
 
FIG. 37 Typical ITC raw data for a 1:1 interaction. Each peak corresponds to one injection of 
ligand into protein solution. The peaks indicative of the power used to compensate for the 
temperature difference to maintain thermal equilibrium. 
 
Integrating these peaks then treats the raw data and doing correction to a per mole 
basis that allows having the binding isotherm. Figure 38 shows the data processing 
result, which gives a sigmoidal curve when the heat is plotted as a function of 
ligand/protein molar ratio.  
 
FIG. 38 ITC processed data gives sigmoidal curve from which binding isotherm is observed. 
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2.5. Protein Expression 
The production of purified recombinant proteins is of great interest for the 
protein chemists84. In addition, Many criteria control the choice of the expression 
approach like cell growth features, expected expression levels, post-translational 
modifications (e.g. phosphorylation), and biological activity of the targeted protein85.  
Different hosts are being used currently by biologists to synthesize and express 
proteins, for example, Escherichia coli, yeast, protozoa, insects and mammalian cells. 
In this research, E.coli had been used as a host to express both proteins of interest; 
human armadillo repeat domain of ß-Catenin and its binding partner TCF4. 
 
2.5.1. Escherichia coli as a host for proteins expression 
Although different expression hosts are available for protein production, the 
most commonly used for industrial purposes still remains the gram-negative bacteria; 
E. coli 86. A disadvantage for therapeutic use of produced recombinant proteins in E. 
coli is the accumulation of endotoxins (lipopolysaccharide), which are pyrogenic in 
humans and other mammals. Proteins that are intended to be used for pharmaceutical 
industry must be purified in a second step to become endotoxin-free87. It’s noteworthy 
that the E.coli lactose utilization (lac operon) has been used as the regulatory element 
to produce the targeted polypeptides.  For lac operon, IPTG, which is a lactose 
analogue, is used as inducer and it allows the production of considerable amount of 
the targeted protein. Moreover, pET vectors are also commonly used in the E.coli 
process of protein production. The main disadvantage of using pET vectors is the 
production of large amount of mRNA, which can in turn cause ribosome destruction 
and cell death88.  
Alternative hosts are now considered to be used as more accessible and affordable. 
For example, eukaryotic systems including mammalian, yeast and insect cell 
expression are becoming easier to use and less expensive89. Cell-free protein synthesis 
also has great potential for overcoming some of the problems of soluble protein 
expression90.  
 
2.5.2. Expression and induction 
To start the expression, the plasmid containing the fusion target protein 
sequence is transformed into the respective E.coli cell line. When starter culture 
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reaches a suitable optical density (OD600), it's diluted 1:100 in the expression culture 
depending on the protein we need. If unlabeled protein is targeted, the expression 
culture is L.B., which contains the appropriate antibiotics. On the other hand, if 15N, 
and/or 13C labeled protein is targeted, the expression culture is done in minimal 
medium (e.g. M9) enriched with 15N labeled ammonium chloride and/or 13C labeled 
glucose. Afterwards, the expression culture is incubated with shaking until OD600 
reaches 0.5. In order to start the induction of protein synthesis, isopropyl-ß-D-
thiogalactopyranosid (12) IPTG, is added to the expression medium91. 
O
HO
OH
S
OH
HO
12  	  
The expression culture is then incubated depending on the nature of the protein and 
then the cells are harvested and resuspended in the appropriate buffer, which depends 
on the nature of the expressed protein. In this investigation, lysis and PBS buffers 
have been used to suspend the pellets for ß-Catenin and TCF4 respectively.  
2.5.3. Dithiothreitol, a protective reagent for SH Group 
Proteins that have cysteine amino acid in their composition tend to form inter- 
and intramolecular disulfide linkages. In order to inhibit the formation of this 
disulfide linkage, a reducing agent; dithiothreitol DTT is added to the buffers used for 
pellets resuspention and for purification92. 
DTT is a strong reducing agent, with a redox potential of -0.33 V at pH 7, while the 
pKa of SH groups is around ~8.3. The reduction of a disulfide bond continues by two 
consecutive thiol-disulfide exchange reactions and ends with the formation disulfide-
bonded six membered ring.  
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FIG. 39 Two steps reduction of protein disulfide linkage using DTT. 
 
2.5.4. Chromatographic purification of protein  
  In this research, proteins purification was performed on fast performance 
liquid chromatography (FPLC) (Äktaexplorer from amersham pharmacia biotech, 
Sweden). The purification techniques used are affinity chromatography and size 
exclusion chromatography. 
2.5.4.1. Affinity chromatography 
2.5.4.1.1. Glutathione-S-transferase tag (GST) 
GST is a 26 KDa tag that is fused to the protein in order to enhance the 
solubility, to allow easy production, selectivity and protection against intracellular 
protease cleavage. The targeted protein is expressed in a plasmid vector that contains 
a GST gene (e.g. pGEX-6P). Later on, the fused protein can be easily purified on a 
GSTrap column, which has immobilized glutathione, then the bound protein is eluted 
using 10mM of reduced glutathione containing buffer93. Moreover, the GST can be 
fused to the N- or C-terminal of the protein of interest. In this investigation, armadillo 
repeat region of β-Catenin and all its mutants were expressed as GSTagged proteins 
and were purified using GSTrap FF 5 ml column (Amersham Pharmacia) which has a 
glutathione ligand linked via 10 carbon linker to highly cross linked 4% agarose. 
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2.5.4.1.2. Polyhistidine tag (His-tag) 
One of the most widely used tags in affinity chromatography purification is 
the polyhistidine tag (which consists usually of 6 histidine residues). Histidine has 
imidazole ring that has electron donor group forming coordinate bond with the 
immobilized metal ion matrix in the histrap column. The charged column has a Ni+2-
NTA matrix (NTA is nitrilotriacetic acid which is a chelating agent in highly cross 
linked agarose matrix and binds Ni+2 by four coordinate sites), which binds to the 
histag, then the bound protein is eluted using high imidazole containing buffer which 
replaces the target protein from the column94.  In this research, TCF4 and its mutants 
were expressed as his-tagged proteins and purified using hitrap-column 5ml 
(Amersham Pharmacia).  
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FIG. 40 Schematic representation of the purification protocol of His-tagged protein using 
Ni+2-NTA matrix column. 
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2.5.4.2. Size exclusion chromatography 
Size exclusion columns consist of dextran covalently bound to highly cross-
linked agarose. The separation range of these columns is different depending on the 
pore size. Column 16/60 Supradex 75 prep grade column gives excellent resolving 
power of proteins in the molecular weight range of 3-70 KDa (mean particle size 34 
µm). This column has been used as a final purification step for β-Catenin and TCF4.  
2.5.5. Protein concentration & purity measurements 
          For measuring the protein samples in NMR, it’s crucial to know the exact 
concentration of our sample and to prove its purity. 
 Protein concentration can be measured accurately using the Lambert-Beer law (A= 
εcl) where A is the absorbance, ε is the molar extinction coefficient of the protein M-
1cm-1, c is the molar concentration M, and l is the path length cm. If the protein 
contains tryptophan(s) residues, the extinction coefficient of 1 tryptophan is (5690 M-
1cm-1 at λ=280nm); the ε of the whole protein is calculated by multiplying 5690 by the 
total number of tryptophan residues. Furthermore, the absorbance is measured at 
wavelength 280 nm95.  
In order to elucidate the purity and correct size of the expressed protein, the sodium 
dodecyl sulfate (SDS) gel electrophoresis technique is used96. The separation of the 
protein is based on its size and charge. The gel consists mainly of acrylamide, 
bisacrylamide, SDS, and a buffer. Upon applying electric field across the gel, the 
negatively charged proteins migrate towards the positive (+) electrode. According to 
the protein molecular weight, it will diffuse differently through the gel. If it’s a small 
protein, it will move more easily through the pores in the gel and diffuse faster, while 
if it’s a large size one, it will experience more difficulty to diffuse and so, it will move 
slower. Hence, Proteins can be separated according to size (molecular weight). 
Moreover, a molecular weight marker is used in order to act as a reference for the 
protein sample size (Dalton Mark VII-L Standard Mixture, Sigma Aldrich). 
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3.1. Materials: 
3.1.1. Microorganisms: 
Organism Strain 
Escherichia (E.) coli BL (21 DE3) 
Rosette (DE3) pLys S 
DH5α 
All strains derived from Novagen  
 
3.1.2. Media for Bacterial Growth: 
1-L.B. Media For ß-Catenin expression Components/ Amounts 
Luria Broth Media 
Autoclaved for 15 min. at 121°C 
Store at 4 °C 
20 g Lauria Broth 
Ampicillin in concentration 100mg/ml 
Add distilled water to volume 1000ml  
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2-M9 Media For TCF4 expression Components/ Amounts 
Autoclaved for 15 min. at 121 °C 
Store at 4 °C 
6 g Na2HPO4 x 2 H2O 
3 g KH2PO4 
0.5 g NaCl 
1 g NH4Cl 
Ampicillin in concentration 100mg/ml 
Chloramphenicol in concentration 
25mg/ml 
Add distilled water to volume 1000ml  
Prior to use add: 
20 ml of 20% glucose 
2 ml of 1 M MgSO4 
0.3 ml CaCl2 
10 ml trace elements solution 
 
 
3-M9 Media For 15N-labelled protein 
expression 
Components/ Amounts 
Autoclaved for 15 min. at 121°C 
Store at 4 °C 
s. M9 medium 
Use 15NH4Cl instead of NH4Cl 
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4-M9 Media For 15N, 13C-labelled 
protein expression 
Components/ Amounts 
Autoclaved for 15 min. at 121°C 
Store at 4 °C 
s. M9 medium 
use 15NH4Cl instead of NH4Cl 
add 3 g 13C-Glucose after autoclaving 
 
3.1.3. Buffers and solutions:  
1-Ampicillin Components/ Amounts 
Ampicillin 
100 mg/ml (≅0.27 M) 
Sterilize by filtration (0.2 µm). 
Store at -20 °C. 
1 g ampicillin 
H2O to a final volume of 10 ml 
 
2-CaCl2 Components/ Amounts 
1 M 
Autoclave at 121°C for 15 min. 
14.7 g CaCl2×2H2O 
H2O to a final volume of 100 ml 
 
3-Chloramphenicol Components/ Amounts 
Chloramphenicol 
25 mg/ml 
Store at -20 °C. 
 
250 mg chloramphenicol 
EtOH to a final volume of 10 ml 
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4-Coomassie staining solution(for 
protein SDS page) 
Components/ Amounts 
0.5% (w/v) Coomassie 
50% (v/v) MeOH 
10% (v/v) HOAc 
Store light protected. 
2.5 g Coomassie Brilliant Blue R-250 
250 ml MeOH (98%) 
50 ml HOAc (99%) 
H2O to a final volume of 500 ml 
 
5-Destaining solution (for protein SDS 
page) 
Components/ Amounts 
30% (v/v) EtOH 
10% (v/v) HOAc 
300 ml EtOH (98%) 
100 ml HOAc. (99%) 
H2O to a final volume of 1 l 
 
6-DNA sample buffer (5x) 
(for agarose gel electrophoresis) 
Components/ Amounts 
20 mM EDTA 
30 % (w/v) Glycerine 
0.5 % (w/v) SDS 
0.1 % (w/v) Bromphenol blue 
Store at 4°C. 
100 µl EDTA 1 M (pH 8.0) 
5 mg bromphenol blue 
1.7 ml glycerine 
125 µl SDS 20 % 
H2O to a final volume of 5 ml 
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7-dNTP Mix (For synthesis of TCF4 
clones) 
Components/ Amounts 
5 mM Datp 
5 mM dCTP 
5 mM dGTP 
5 mM dTTP 
Aliquote and store at -20 °C. 
5 µl dATP 100 mM 
5 µl dCTP 100 mM 
5 µl dGTP 100 mM 
5 µl dTTP 100 mM 
H2O to a final volume of 100 µl 
 
8-Dithiothreitol (DTT) Components/ Amounts 
1 M 
Sterilize by filtration (0.2 µm). 
Store at -20 °C. 
 
1.54 g dithiothreitol 
H2O to a final volume of 10 ml 
 
9-EDTA buffer Components/ Amounts 
0.05 M 
 
9.306 g EDTA 
H2O to a final volume of 500 ml add 5 
M NaOH to reach pH=7 
 
10-Glucose Components/ Amounts 
1 M 
Sterilize by filtration (0.2 µm). 
Store at 4 °C. 
19.8 g Glc×H2O 
H2O to a final volume of 100 ml 
 
Experimental 
 
64  
11-HEPES buffer (for ß-Catenin 
reductive methylation) 
Components/ Amounts 
10 mM 2-[4-(2-hydroxyethyl)piperazin-
1-yl]ethanesulfonic acid 
150mM NaCl 
1mM DTT 
Autoclave at 121 °C for 15 min. 
2.38 g HEPES 
8.76 g NaCl 
1 ml DTT 
800 ml H2O 
Adjust pH to 7.4 by adding conc HCl 
and bring volume to 1 l. 
 
12-Imidazole buffers (for TCF4 
chelating HiTrap column) 
Components/ Amounts 
20 mM trizma base 
500 mM NaCl 
2.5% w/v glycerol 
a-10mM imidazole (low-imidazole 
buffer) 
b-500 mM imidazole (Hi-imidazole 
buffer) 
2.42 g Trizma base 
29.2 g NaCl 
25 g glycerol 
a-0.68 g imidazole 
 
b-34.04 g imidazole 
900 ml H2O 
Adjust pH to 7.4 by conc HCl 
Bring volume to 1 l. 
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13-Isopropyl β-D-1-
thiogalactopyranoside (IPTG) 
Components/ Amounts 
1 M 
Sterilize by filtration (0.2 µm). 
Store at 4 °C. 
2.4 g IPTG (238.25 g/mol) 
H2O to a final volume of 10 ml 
 
14-Kanamycin Components/ Amounts 
25 mg/ml 
Sterilize by filtration (0.2 µm). 
Store at -20 °C. 
250 mg Kanamycin monosulfate 
H2O to a final volume of 10 ml 
 
15-Laemmli buffer (Electrophoresis 
running buffer for protein SDS page) 
Components/ Amounts 
25 mM Tris 
190 mM Glycine 
0.1 % SDS. 
250 mg Kanamycin monosulfate 
H2O to a final volume of 10 ml 
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16-Lysis buffer (ß-Catenin) Components/ Amounts 
PBS buffer (pH 7.4) 
1 mM Na3VO4 
20 mM DTT 
0.26 g KH2PO4 
2.17 g Na2HPO4 7H2O 
8.71 g NaCl 
0.09 g Na3VO4 
20 ml DTT 
800 ml H2O, adjust pH to 7.4 and 
bring volume to 1 l. 
 
17-Nickel Chloride solution (For 
charging of Chelating Hitrap Column) 
Components/ Amounts 
0.1 M NiCl2 
 
1.29 g anhydrous NiCl2 
Add H2O to bring volume to 100 ml 
 
18-PBS buffer (ß-Catenin & TCF4) Components/ Amounts 
140mM NaCl 
2.7 mM KCl 
10mM Na2HPO4 
1.8mM KH2PO4 
2mM DTT 
8.17 g NaCl 
0.2 g KCl 
1.77 g Na2HPO4 
0.24 g KH2PO4 
2 ml DTT 
800 ml H2O, adjust pH to 7.4 and 
bring volume to 1 l. 
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19-Protein size marker (For protein 
SDS page) 
Components/ Amounts 
1.4 µg/µl total protein 
Store at -80°C. 
2.1 mg SDS7 Dalton mark (1 vial) 
Protein sample buffer 1× to a final 
volume of 1.5 ml 
 
20-2x Protein sample buffer (For 
protein SDS page) 
Components/ Amounts 
120 mM Tris×HCl, pH 6.8 
6 % (w/v) SDS 
20 % (v/v) Glycerine 
0.01 % (w/v) Bromphenol blue 
10 % (v/v) ß-Mercaptoethanol 
Store at -20 °C. 
Thaw only once. 
1.2 ml Tris×HCl 1 M (pH 6.8) 
3 ml SDS 20 % 
2 ml glycerine 
1 mg bromphenol blue 
H2O to a final volume of 9 ml 
Add 100 µl of ß-mercaptoethanol to 
900 µl of buffer, then store at 4°C. 
 
21-Stop Mix (5x) for DNA restriction Components/ Amounts 
20 mM EDTA 
30 % Glycerin 
0.5 % SDS 
0.1 % Bromphenolblue 
0.1ml 1 M EDTA (pH=8.0) 
1.7 ml Glycerin 
0.125 ml 20 % SDS 
2 ml 0.5% Bromphenolblue 
H2O to a final volume of 5 ml. 
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22-TBE buffer  (Running buffer for 
agarose gel) 
Components/ Amounts 
10× 
pHcalc 8.3 
0.89 M Tris 
0.89 M Boric acid 
0.02 M EDTA 
Autoclave at 121 °C for 15 min. 
108 g tris base 
55 g H3BO3 
7.44 g EDTA Na2×2H2O 
H2O to a final volume of 1 l 
 
23-TEV-protease buffer   Components/ Amounts 
50 mM trizma base 
0.5 mM EDTA 
1mM DTT 
Autoclave at 121 °C for 15 min. 
6.057 g tris base 
0.186 g EDTA 
1 ml DTT 
800 ml H2O 
Adjust pH to 8 by adding conc HCl 
and bring volume to 1 l. 
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24-Tris.HCl buffer  (for ß-Catenin size 
exclusion chromatography) 
Components/ Amounts 
100 mM trizma base 
150mM NaCl 
1mM DTT 
Autoclave at 121 °C for 15 min. 
12.1 g trizma base 
8.76 g NaCl 
1 ml DTT 
800 ml H2O 
Adjust pH to 7.4 by adding conc HCl 
and bring volume to 1 l. 
 
25-Tris.Glutathione buffer  (elution 
buffer for ß-Catenin GSTrap column) 
Components/ Amounts 
50 mM trizma base 
20mM reduced Glutathione 
Autoclave at 121 °C for 15 min. 
6.05 g trizma base 
6.14 g reduced glutathione 
800 ml H2O 
Adjust pH to 7.4 by adding conc HCl 
and bring volume to 1 l. 
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3.2. Methods, Results and Discussions: 
3.2.1. Expression of GST-tagged Armadillo Repeat region 
of ß-Catenin protein: 
1-Transformation: 
To 100 µl of BL21 (DE3) E.coli cell line, 10 ng of β-Catenin Pgex6p 
vector (Ampicillin resistant) were added in eppendorf tube. The mixture was left 
in ice bath for 10 minutes, then in water bath at 42 °C for 1.5 minutes, in ice bath 
again for 2 minutes. To this mixture, 300 µl of L.B. medium was added in the 
eppendorf (1 bacteria cell line volume: 3 L.B. medium), then shacked for 45 
minutes in shaker at 37 °C. An inoculum of 50 µl of the plasmid/bacteria mixture 
was transferred to Luria–Broth (LB)-Agar plate that contains ampicillin, spreaded 
then incubated in the incubator at 37 °C overnight. 
2- Pre-culture & overnight culture: 
In a mixture of 50 ml sterilized L.B. & 50 µl ampicillin, one colony of the 
grown bacteria was added and then put in the shaker overnight at 30 °C. 
3- Expression Culture: 
To 1 l of sterilized L.B., 1 ml ampicillin was added. Then 10 ml of the 
overnight culture (to have 1:100 concentration) were supplemented. Shaking took 
place at 37 °C and then Optical Density (OD600) was measured every 45 minutes 
until (OD600) =0.5 was reached. Finally, 1 ml of 4 M IPTG was added to the 1 l 
(to have final concentration of 0.4 mM IPTG). The mixture was shacked 
overnight at 20 °C. 
 4- Harvesting: 
The OD600 was measured to be sure that it increased overnight. 
Centrifugation (4000 rpm, 4 °C, 20 minutes) was used to harvest the cells. The 
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pellets were resuspended in 25 ml lysis buffer and the aliquot was frozen in liquid 
nitrogen for 5 minutes and stored at -80°C until purification. 
5- Sonication & DNA precipitation: 
The sample is thawed and a few amount of lysozyme is added, then cells 
were lysed by ultrasonication. The sample was centrifuged (18000 rpm, 4 °C, 20 
minutes) to get rid of the broken cells. To the clear supernatant, 10% w/v 
streptomycin solution was added to precipitate the DNA in a ratio 1:10. The 
sample was again centrifuged (18000 rpm, 4 °C, 20 minutes) to remove the 
precipitated DNA. 
6-Chromatographic purification: 
The chromatographic purification strategy has been applied in a series to run 
on a currently existing FPLC chromatographic system ÄKTAE Explorer (Amer-
sham Biosciences, Uppsala, Sweden). Chromatographic profiles continuously 
monitor absorbance (260 and 280 nm). 
a- GSTrap FF 5 ml column: 
The buffer solutions were degased using a water jet pump and filtrated 
through a ZapCapS bottle top filter (0.2 µm). The column was equilibrated with 5-
column volume of the binding buffer (PBS buffer). The sample supernatant 
obtained from the last step was loaded on the column in a flow rate 1 ml/minute 
and the loading was repeated five times to ensure binding of the GST-tag protein 
because of the low binding kinetics.  
Afterwards, the column was washed with PBS buffer until the absorbance return 
to zero and the base line is stable. The sample was then eluted using the elution 
buffer (Tris/Glutathione buffer). Based on the chromatogram, the protein fractions 
were concentrated to a volume of 3ml to be used for the next size exclusion 
chromatography. 
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FIG. 41 Chromatogram of the GST-tagged armadillo repeat β-­‐catenin	  after loading on 
GSTrapp FF column and subsequent elution with buffer containing glutathione. The 
fractions containing the protein are tracked by the absorbance at 260 nm (in red) and 280 
nm (in blue). 
 
b- Gel filtration Chromatography (size exclusion Hiload column 
16/60): 
The column is equilibrated with 1.5 column volume of Tris-HCl buffer 
until the base line is stable. The sample Obtained from the GSTrap FF column 
was injected through a 5 ml loop and then the sample fractions were eluted using 
the Tris-HCl running buffer. The protein comes out from the column based on its 
size (85 KDa). Based on the obtained chromatogram, the protein fractions were 
collected.  
 
 
Experimental 
 
73  
           
FIG. 42 Chromatogram of the GST-tagged armadillo repeat β-­‐Catenin	  after loading on 
Hiload 16/60 and subsequent elution. The fractions containing the protein are tracked by 
the absorbance at 260 nm (in red) and 280 nm (in blue). The first peak is the protein's 
while the second is DNA. 
 
7- SDS polyacrylamide gel Electrophoresis (SDS-page of proteins) 
The gel was put into a running cell filled with Laemmli buffer. The 
different sample fractions mixed with 2x protein buffer (10 µl protein + 10 µl 2x 
buffer) were loaded onto the gel. Use protein size marker for referencing. The gel 
was run at 200 V for 40 min. Afterwards, the gel was stained with Coomassie 
staining solution for at least 30 min. Later, the gel got destained using the 
destaining solution until the gel is colourless again, except the protein bands. A 
picture of the gel was taken with a Gel Doc System (Sony). 
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FIG. 43 Purified human GST-tagged armadillo repeat β-Catenin protein. Coomassie 
stained 15% SDS-polyacrylamide gels show pure fractions of recombinant protein 
after GSTrap and gel filtration columns. Numbering of lanes (A-E) corresponds to 
different collected fractions based on the chromatogram of the gel filtration step. 
8- Concentration and quantification of the protein sample: 
The protein sample is transferred to a concentration device (centricon), 
which has a cut off value of 10 KDa. The centricon was then centrifuged (4000 
rpm, 4 °C) for the suitable time until the required concentration is reached. The 
excess buffer passes through the membrane while the protein sample is retained 
above the membrane. 
To quantify the concentration of the final volume of the protein, UV absorbance at 
280 nm was measured. The extinction coefficient for ß-Catenin is 75000 M-1cm-1. 
The protein was obtained in a maximum concentration of 80 µM. At higher 
concentrations, it started to aggregate and precipitate. 
The expressed armadillo repeat domain of human ß-Catenin is the core region (the 
residues 134-671). It consists of 12 repeats; each is 3 α-helices. The sample was 
sent for sequencing in LGC GENOMIC Company, Berlin, Germany. 
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Human ß-Catenin armadillo repeats Sequence  
        10         20         30         40         50         60  
HAVVNLINYQ DDAELATRAI PELTKLINDE DQVVVNKAAV MVHQLSKKEA SRHAIMRSPQ  
 
        70         80         90        100        110        120  
MVSAIVRTMQ NTNDVETARC TAGTLHNLSH HREGLLAIFK SGGIPALVKM LGSPVDSVLF  
 
       130        140        150        160        170        180  
YAITTLHNLL LHQEGAKMAV RLAGGLQKMV ALLNKTNVKF LAITTDCLQI LAYGNQESKL  
 
       190        200        210        220        230        240  
IILASGGPQA LVNIMRTYTY EKLLWTTSRV LKVLSVCSSN KPAIVEAGGM QALGLHLTDP  
 
       250        260        270        280        290        300  
SQRLVQNCLW TLRNLSDAAT KQEGMEGLLG TLVQLLGSDD INVVTCAAGI LSNLTCNNYK  
 
       310        320        330        340        350        360  
NKMMVCQVGG IEALVRTVLR AGDREDITEP AICALRHLTS RHQEAEMAQN AVRLHYGLPV  
 
       370        380        390        400        410        420  
VVKLLHPPSH WPLIKATVGL IRNLALCPAN HAPLREQGAI PRLVQLLVRA HQDTQRRTSM  
 
       430        440        450        460        470        480  
GGTQQQFVEG VRMEEIVEGC TGALHILARD VHNRIVIRGL NTIPLFVQIL YSPIENIQRV  
 
       490        500        510        520        530  
AAGVLCELAQ DKEAAEAIEA EGATAPLTEL LHSRNEGVAT YAAAVLFRMS EDKPQDYK  
 
 
Number of amino acids: 538 
 
Molecular weight: 58773.2 
 
Theoretical pI: 8.26 
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Amino acid composition:  
Residue Number of residues %Composition 
Ala 57 10.6% 
Arg 30 5.6% 
Asn 27 5.0% 
Asp 18 3.3% 
Cys 11 2.0% 
Gln 29 5.4% 
Glu 31 5.8% 
Gly 34 6.3% 
His 19 3.5% 
Ile 31 5.8% 
Leu 71 13.2% 
Lys 22 4.1% 
Met 16 3.0% 
Phe 6 1.1% 
Pro 19 3.5% 
Ser 24 4.5% 
Thr 34 6.3% 
Trp 3 0.6% 
Tyr 10 1.9% 
Val 46 8.6% 
 
Total number of negatively charged residues (Asp + Glu): 49 
Total number of positively charged residues (Arg + Lys): 52 
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Atomic composition: 
 
Carbon        C       2580 
Hydrogen    H       4247 
Nitrogen      N        747 
Oxygen        O        761 
Sulfur           S         27 
Formula: C2580H4247N747O761S27 
Total number of atoms: 8362 
 
Extinction coefficients: 
 
Extinction coefficient is in units of M-1 cm-1, at 280 nm measured in water. 
 
Ext. coefficient    32025 
Abs 0.1% (=1 g/l) 0.545, assuming all pairs of Cys residues form cystines 
 
Ext. coefficient    31400 
Abs 0.1% (=1 g/l) 0.534, assuming all Cys residues are reduced 	  
GSTag 
        10         20         30         40         50         60  
MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EEPNLPYYID  
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        70         80         90        100        110        120  
GDVKLTQSMA IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV  
 
       130        140        150        160        170        180  
DFLSKLPEML KMFEDRLCHK TYLNGDHVTH PDFMLYDALD VVLYMDPMCL DAFPKLVCFK  
 
       190        200        210        220  
KRIEAIPQID KYLKSSKYIA WPLQGWQATF GGGDHPPKSD LVPRGSP  	  
Number of amino acids: 227 
 
Molecular weight: 26389.6 
 
Theoretical pI: 5.91 
Number of amino acids: 227 
 
Molecular weight: 26389.6 
 
Theoretical pI: 5.91 
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Amino acid composition: 
 
Residue Number of residues %Composition 
Ala 10 4.4% 
Arg 10 4.4% 
Asn 4 1.8% 
Asp 18 7.9% 
Cys 4 1.8% 
Gln 5 2.2% 
Glu 17 7.5% 
Gly 15 6.6% 
His 6 2.6% 
Ile 13 5.7% 
Leu 28 12.3% 
Lys 21 9.3% 
Met 9 4.0% 
Phe 8 3.5% 
Pro 15 6.6% 
Ser 10 4.4% 
Thr 6 2.6% 
Trp 4 1.8% 
Tyr 14 6.2% 
Val 10 4.4% 
 
Total number of negatively charged residues (Asp + Glu): 35 
Total number of positively charged residues (Arg + Lys): 31 
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Atomic composition: 
 
Carbon        C       1204 
Hydrogen    H       1861 
Nitrogen      N        303 
Oxygen        O        337 
Sulfur           S         13 
 
Formula: C1204H1861N303O337S13 
Total number of atoms: 3718 
 
Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water. 
 
Ext. coefficient    43110 
Abs 0.1% (=1 g/l) 1.634, assuming all pairs of Cys residues form cystines 
 
Ext. coefficient    42860 
Abs 0.1% (=1 g/l) 1.624, assuming all Cys residues are reduced 
 
Total weight of the synthesized human GST-tagged armadillo repeat ß-Catenin = 
58773.2 + 26389.6 = 85 K.D. 
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3.2.2. Expression of His-tagged Transcription factor 
(TCF4): 
1-Transformation: 
To 100 µl of Rosetta BL5 E.coli cell line (chloramphenicol resistant), 10 
ng of TCF4 pet-20b vector (Ampicillin resistant) were added in eppendorf tube. 
The mixture was left in ice bath for 10 minutes, then in water bath at 42°C for 1.5 
minutes, in ice bath again for 2 minutes. 300 µl of L.B. medium were then added 
(1 bacteria cell line volume: 3 L.B. medium), then the eppendorf tube was shaked 
for 45 minutes at 37°C. 50 µl of the plasmid/bacteria mixture was applied on 
Luria–Broth (LB)-Agar plate which contains chloramphenicol and ampicillin. 
After spreading the inoculum, the plate was left for 5 minutes, inverted and kept 
in incubator at 37°C overnight. 
2- Pre-culture: 
To 3 ml of sterilized L.B., 3 µl chloramphenicol and 3 µl ampicillin were 
added. Afterwards, one colony of the grown bacteria was pipette into the prepared 
L.B. medium and then put in the shaker for 4 hours at 37°C. 
3- Overnight culture: 
To 50 ml of sterilized L.B., 50 µl chloramphenicol and 50 µl ampicillin 
were added. 100 µl of the previously prepared pre-culture was mixed with this 
mixture. The prepared culture was shacked overnight at 32°C. 
4- Expression Culture: 
To 1 l of sterilized M9 (15N or 13C & 15N labeled), 1 ml of 
chloramphenicol and 1 ml ampicillin were added. In addition, 10 ml of the 
overnight culture (to have 1:100 ratio) were added. Shaking took place at 37°C 
and then Optical Density (OD600) was measured every 45 minutes until (OD600) 
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=0.5 was reached. Finally, 1 ml of 4 M IPTG was added to the 1 l (to have final 
concentration of 0.4 mM IPTG). The mixture was shacked for 4 hours at 37°C. 
5- Harvesting: 
The cells were harvested by centrifugation (4000 rpm, 4 °C, 20 minutes). 
The pellets were resuspended in 25 ml PBS buffer and the aliquot was frozen in 
liquid nitrogen for 5 minutes and stored at -80°C until purification. 
6- Sonication: 
After thawing the sample, one tablet of protease cocktail inhibitor was 
added, and then cells were lysed by ultra sonication. The sample was centrifuged 
(18000 rpm, 4 °C, 20 minutes) to get rid of the broken cells. 
7-Chromatographic purification: 
a- Hitrap chelating column: 
The buffer solutions were degased using a water jet pump and filtrated 
through a ZapCapS bottle top filter (0.2 µm). 
The column was recharged with 3 ml of 0.1 M NiCl2 and washed with 5-column 
volume of H2O. 
The column was equilibrated with 5 column volume of the binding buffer (low 
imidazole buffer), then with 5 column volume of the eluting buffer (hi-imidazole 
buffer), and eventually, with 5 column volume of the binding buffer again.  
The TCF4 sample supernatant obtained from the last step was loaded on the Ni+2 
charged column in a flow rate 1 ml/minute to allow binding of the protein 
histidine tag to the Ni+2. The column was washed with low-imidazole buffer till a 
stable base line was obtained. The sample fractions were eluted during a gradient 
elution over 75 minutes (100% target concentration of the hi-imidazole buffer). 
Finally, based on the chromatogram, the protein fractions were concentrated to a 
volume of 3 ml to be used for the next size exclusion chromatography. 
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FIG. 44 Chromatogram of the His-tagged TCF4 after loading on Hitrap chelating column 
and subsequent elution with buffer gradient of low and hi-imidazole. The fractions 
containing the protein are tracked by the absorbance at 260 nm (in red) and 280 nm (in 
blue). The green line shows the gradient increase in the concentration of imidazole. 
 
b- Gel filtration Chromatography (size exclusion Hiload column 
16/60): 
The column was equilibrated with 1.5 column volume of PBS buffer until 
the base line is stable. The sample Obtained from the previous chromatographic 
step was concentrated to 3 ml and injected through a 5 ml loop. Afterwards, the 
sample fractions were eluted using the PBS running buffer. The protein comes out 
from the column according to its size (7 KDa). Based on the obtained 
chromatogram, the protein fractions were collected. 
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FIG. 45 Chromatogram of the His-tagged TCF4 after loading on Hiload 16/60 and 
subsequent elution with PBS buffer. The fractions containing the protein are tracked by 
the absorbance at 260 nm (in red) and 280 nm (in blue). The large peak is the protein's. 
 
8- SDS polyacrylamide gel Electrophoresis (SDS-page of proteins) 
The gel was run in the same way described before and different fractions 
based on the chromatogram have been tested. 
 
 
FIG. 46 Purified His-tagged TCF4 protein. Coomassie stained 15% SDS-
polyacrylamide gels show pure fractions of recombinant protein after Chelating 
hitrap and gel filtration columns. Numbering of lanes (A-F) corresponds to the 
fractions collected based on the chromatogram of the gel filtration step. 
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9- Concentration and quantification of the protein sample: 
The protein sample is transferred to a concentration device (centricon) 
with a cut off value smaller than the molecular weight of the protein. The 
centricon was then centrifuged (4000 rpm, 4 °C) until the required concentration 
is reached. 
To quantify the concentration of the obtained protein, UV absorbance at 280nm 
was measured. The extinction coefficient for His-tagged TCF4 is 5500 M-1cm-1. 
The protein was obtained in maximum concentration 1 mM. The sample was sent 
for sequencing in LGC GENOMIC Company, Berlin, Germany. 
His-tagged Tcf4 sequence 
        10         20         30         40         50         60  
MPQLNGGGGD DLGANDELIS FKDEGEQEEK SSENSSAERD LADVKSSLVN ESETNKNWLE  
 
 
HHHHH  
 
Number of amino acids: 65 
Molecular weight: 7200.5 
Theoretical pI: 4.52 
Amino acid numbers and percent composition:  
Residue Number of residues %Composition 
Ala 3 4.6% 
Arg 1 1.5% 
Asn 6 9.2% 
Asp 6 9.2% 
Cys 0 0% 
Gln 2 3.1% 
Experimental 
 
86  
Glu 10 15.4% 
Gly 6 9.2% 
His 5 7.7% 
Ile 1 1.5% 
Leu 6 9.2% 
Lys 4 6.2% 
Met 1 1.5% 
Phe 1 1.5% 
Pro 1 1.5% 
Ser 8 12.3% 
Thr 1 1.5% 
Trp 1 1.5% 
Tyr 0 0% 
Val 2 3.1% 
 
Total number of negatively charged residues (Asp + Glu): 16 
Total number of positively charged residues (Arg + Lys): 5 
Atomic composition: 
Carbon        C        299 
Hydrogen    H        459 
Nitrogen      N         91 
Oxygen        O        115 
Sulfur           S          1 
 
Formula: C299H459N91O115S1 
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Total number of atoms: 965 
 
Extinction coefficients: 
Ext. coefficient     5500 
Abs 0.1% (=1 g/l)  0.764 
------------------------------------------------------------------------------------ 
Total weight of the synthesized human His-tagged TCF4 = 7 K.D. 
3.2.3. Expression of his-tagged truncated TCF4 mutants 
 Two truncated versions out of TCF4 have been expressed; fragment which has 
the residues from 10-30 and a fragment, another that has the residues from 32-52. 
I-Cloning of DNA fragments 
*In the PCR tube mix, the following components have been added 
5 µl of 10x PFU buffer+MgSO4 
1 µl of 10 µM sense primer 
1 µl of 10 µM anti-sense primer 
2 µl of 50 ng/ µl template TCF4-plasmid 
5 µl of dNTP  
0.5 µl PFU-DNA polymerase 
35.5 µl water (to have a final volume of 50 µl) 
*PCR machine program: 
1- 95 °C 30 seconds 
2- 95 °C 30 seconds  
3- 55 °C 1 minute 
4- 68 °C 30 seconds 
5- procedures from 2-4 were repeated 30 times 
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6- 72 °C 10 minutes 
7- hold at 4°C 
*Digestion of the DNA with restriction enzymes (Not1, Nco1): 
The PCR products were purified using PCR purification kit (Qiagen), and then to 
the eluted purified DNA, the following were added 
3 µl of buffer O+  
1 µl Not 1 restriction enzyme (10 u/ µl )  
1 µl Nco1 restriction enzyme (10 u/ µl ) 
Digestion was done at 37 °C overnight 
*Ligation: 
50 ng of vector pET-gB1 (kanamycin resistant) 
6-fold molar excess of insert DNA 
2 µl of 10x T4 DNA ligase buffer 
0.5 µl T4 DNA ligase 
H20 to final volume of 20 µl 
The mixture is kept at 24°C for 1 h. 
*Transformation of the ligated DNA into DH-5α 
The 20 µl of the ligation mixture was transformed into 100 µl aliquot of E.coli 
DH-5α strain. After overnight growth, one colony was transferred into 10 ml of 
sterilized L.B. + 10 µl of kanamycin and allowed to grow overnight at 37°C. The 
L.B. was then centrifuged and the pellets were treated with miniprep kit (Qiagen) 
to obtain the purified DNA plasmid.  
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II- Expression of the targeted 15N-labeled TCF4 mutants 
The DNA plasmids of the 2 TCF4 mutants were transferred into 100 µl of 
Rosetta BL5 E.coli cell line (chloramphenicol resistant) and the same procedures 
used to express the wild type TCF4 were followed. 
His-tagged mutant-Tcf4 sequence (N-terminal part) 
        10         20         30         40         50         60  
MKHHHHHHPM KQYKLILNGK TLKGETTTEA VDAATAEKVF KQYANDNGVD GEWTYDDATK  
 
        70         80         90        100  
TFTVTEGSGS GSENLYFQGA MGCEDLGAND ELISFKDEGE QEE  
 
 
Where the bold letters represent the sequence of the truncated TCF4  
peptide, while the rest is the histag and the Gb1 fusion part. 
Number of amino acids: 103 
Molecular weight: 11426.3 
Theoretical pI: 4.76 
Extinction coefficient: 11460 
 
His-tagged mutant-Tcf4 sequence (C-terminal part) 
        10         20         30         40         50         60  
MKHHHHHHPM KQYKLILNGK TLKGETTTEA VDAATAEKVF KQYANDNGVD GEWTYDDATK  
 
        70         80         90        100  
TFTVTEGSGS GSENLYFQGA MGCSENSSAE RDLADVKSSL VNE 
 
 
Where the bold letters represent the sequence of the truncated TCF4  
peptide, while the rest is the histag and the Gb1 fusion part. 
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Number of amino acids: 103 
Molecular weight: 11309.3 
Theoretical pI: 5.39 
Extinction coefficient: 11460 
III- Cleavge of the Gb1- fusion using Tev-protease 
 In order to perform the NMR measurements on the expressed TCF4 
mutants, it was crucial to get rid of the Gb1 fusion using the Tev-protease 
enzyme. Tev protease minimal recognition site is the sequence (ENLYFQG), 
where the cleavage occurs between Q and G residues. 
The expressed truncated TCF4 peptides were dialyzed against Tev-buffer 
overnight. 1 mg of Tev protease was added to each 50 mg of the protein and the 
mixture was incubated overnight at 4°C. The mixture was then transferred into a 
centricon with cut-off 3 KDa, therefore, the cleaved peptide that has a size of 2.5 
KDa would pass to the flow through, while the Gb1 fusion protein was retained 
on the membrane. The flow through was then dialyzed against water and froze 
dried. Eventually, for NMR measurements, the dried sample was dissolved in 450 
µl of PBS buffer and 50 µl of D2O. 
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3.2.4. NMR experiments to measure the binding between 
the meta-structure predicted ligands and the human 
armadillo repeat region of ß-Catenin: 
Two ligands have been taken at the beginning of the project as lead 
compounds to be investigated. One compound was predicted by meta-structure to 
be binding with the armadillo repeat core region of human ß-Catenin; fluorescein 
sodium (13). The predicted ligand was hypothesized based on similarity of the 
met-structure parameters between catenin and human serum albumin.  
 
FIG. 47 Similarity between beta-catenin known ligands and ligands derived from meta-
structure calculations. The similar structures are highlighted in black. (Figure is adapted 
from Henen et al.97) 
 
In addition, N'(furan-2ylmethylene)-2-phenoxybenzohydrazide (14), which was 
reported as a potential ligand for catenin based on NMR and ITC studies83, was 
also considered.  
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O ONaO
COONa
13
O
HNOC
N
CH
O
14  
In order to investigate the binding of different ligands with ß-Catenin, fluorescein 
sodium (13) and a fluorescein derivative; Eosin Y sodium (15) have been tested 
for binding using 1D 1H-saturation transfer difference NMR (STD) experiment. 
Moreover, we considered testing the binding of compound (14) as two separate 
parts; sodium 2-phenoxybenzoate (16) and 5-methylfurfural (17) using the same 
NMR experiment. 
O ONaO
COONa
Br
Br
Br
Br
15
O
NaOOC
O
H3C CHO
16 17  
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3.2.4.1. 1H-Saturation Transfer Difference NMR (1H-STD): 
All spectra were acquired at 25 °C on a Varian INOVA 500 MHz 
spectrometer. The ligands were purchased from Sigma/Aldrich Company. Data 
were collected from a ligand and the expressed ß-Catenin mixture in a final 
concentration of 1 mM ligand and 30 µM protein. The ligands and the protein 
mixtures were all in Tris-buffer at pH=7.4 with 10% D2O to lock the field. For 
each ligand 1D 1H-NMR experiment was recorded prior to The STD experiment. 
Moreover, negative control STD experiments were performed on 1mM solutions 
of the ligands in absence of the protein. Selective pre-saturation of the protein 
protons was achieved by a train of 50–100 Gauss shaped pulses of 50 ms with a 
strength of (c/2p)B1 = 26 Hz, the protein resonances were removed from the 
spectra using T1ρ filter. The on resonance irradiation of the protein was done at -
1.0 ppm. Off-resonance irradiation was applied at 100 ppm, where no protein 
signals could be detected. The usual relaxation delay was set to 2 s. To eliminate 
protein resonances from the spectrum, a spin-lock ﬁlter (T1ρ-ﬁlter) was used. The 
spectra were processed by multiplication with an exponential line broadening 
function of 0.3–1 Hz prior to Fourier transformation. The data were processed and 
analyzed with NMRPipe software98. In addition, STD was measured for 0.5 mM 
of compound 16 and with saturation time 1s to calculate STD-AF as a parameter 
of binding. The STD-AF was calculated from the following equation99: 
STD − AF = ε(I0 − Isat)/I0 
Where ε is the ratio between ligand and protein concentration, I0 −Isat is the 
normalized signal intensity of the ligands’ protons after protein saturation, and I0 
the signal intensity of the ligand in the reference 1D experiment. 
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Table 1: Recording parameters of the performed 1D 1H-STD experiments 
Spectral width [Hz] 
Number of points 
Number of scans 
6000.2 
2996 
128 
 
1D-1H NMR spectra for 1 mM of compounds 13, 15, 16 and 17 were 
initially recorded and they showed the following spectral data (table 2). 
Table 2: 1D 1H-NMR data of compounds 13, 15, 16 and 17. 
Compound 
Number and 
concentration 
(w/v) 
1H-NMR 
(Tris-buffer/10% D2O) 
13 
0.037 g/ 100 
ml 
6.57 (m, 4H, H1 & H2, & H7& H8), 6.72 (m, 2H, H4 & H5), 
7.26 (d, 1H, H3'), 7.71 (dt, 1H, H5'), 7.79 (dt, 1H, H4'), 7.99 (d, 
1H, H6'). 
15 
0.068 g/ 100 
ml 
7.25 (d, 1H, H3'), 7.48 (s, 2H, H1& H8), 7.65 (m, 2H, H4'& H5'), 
7.78 (d, 1H, H6'). 
16 
0.0236 g/ 100 
ml 
6.75 (d, 3H, H2’, H4’, H6’), 6.86 (d, 2H, H3’, H5’), 6.99 (t, 1H, 
H6), 7.08 (t, 1H, H4), 7.21 (m, 1H, H5), 7.45 (d, 1H, H3)  
17 
0.011 g/ 100 
ml 
1.8 (s, 3H, CH3), 2.95 (s, 2H, CH2), 6.35 (s, 1H, H3), 7.45 (s, 
1H, H2) 
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Results & Discussion 
1D 1H-STD NMR was recorded later for each ligand and protein mixture. 
Compounds 13, 15, and 16 showed positive STDs as the resonances of these 
compounds are observed while compound 17 showed zero STD. Since 
magnetization transfer in STD experiment moves from the protein to the small 
molecule ligand and is detected as signal enhancement of the ligand after its 
dissociation from the protein, this observation strongly support that these 
compounds which showed positive STD are binding to the ß-Catenin. The 
negative control experiments all showed zero STD as expected. (Results are 
shown in figure 48). Moreover, sodium 2-phenoxybenzoate (16) showed STD-AF 
value of 0.63. 
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FIG. 48 1D 1H STD spectra of 30 µM solution of β-Catenin	  with 1 mM aqueous solution 
of different ligands. The corresponding negative control in absence of the protein is 
shown below each spectrum. A) Fluorescein sodium. B) Eosin Y. C) Sodium 2-
phenoxybenzoate. D) 5-Methylfurfural. (Ligands A and B figures are adopted from 
Henen et al.97). 
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3.2.4.2. Cross-Relaxation during Adiabatic Fast Passage: 
In this experiment, AFP-NOESY measures the homonuclear (1H-1H) cross 
relaxation rates (NOEs and ROEs) during adiabatic fast passage (AFP). This 
involved adiabatic fast passage radio frequency (RF) pulses with a parabolic 
phase modulation leading to a linear frequency sweep through a considerably 
large spectral window. The experiment was done to a sample of fluorescein 
sodium (13) without protein and to a mixture of 1 mM of fluorescein sodium (13) 
and 30 µM of ß-Catenin in tris-buffer/10% D2O at different AFP spin lock power. 
Initially, to invert protons number H1, H2, H7 and H8, a selective 180° IBURP1 
pulse centered at 6.5 ppm with inversion bandwidth 0.34 ppm was applied. On the 
other hand, to invert protons number H4', H5' and H6', a selective 180° IBURP 
pulse centered at 7.61 ppm with inversion bandwidth 0.34 ppm was applied (used 
IBURP pulses had a length of 9.58 ms and power of 24 db). Afterwards, different 
strength AFP spin lock fields were applied 5 kHz downfield of the carrier 
frequency for 400 ms and swept over 10 kHz in the upfield direction with 10% 
apodization “at the beginning (sinusoidal) and at the end (cosinusoidal)”. 
Eventually, a read-out 90° pulse was applied. 
 
The NOE between different protons in compound 13 was measured as a function 
of AFP spin lock power (sin2θ). The different strength of the applied spin lock 
field gave rise to the following sin2θ: 0.0607, 0.0760, 0.0948, 0.1180, 0.146, 
0.1808, 0.2221, 0.2710, 0.3277, 0.3919, 0.4623, 0.5365, and 0.6110. 
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Results & Discussion 
In the first set of experiments, peaks of protons H1, H2, H7 and H8 were 
inverted and the NOE effect on peaks of protons H4 and H5 was observed. The 
data shown in figure 49A clearly demonstrated that the behavior of compound 13 
is now a behavior of large molecule and these protons are binding to the protein 
present in the solution.  
In the second set of experiments, peaks of protons H4', H5' and H6' were inverted, 
and the NOE effect on peaks of protons H1, H2, H7 and H8 was observed. The data 
shown in figure 49B demonstrated the behavior of large molecule as the NOE and 
ROE differ in their sign (NOE enhancement is  -100% and ROE enhancement is 
+200%) leading to dependence of the cross relaxation rate is on the strength of the 
applied AFP spin lock field. It can be concluded from this that these protons bind 
to the armadillo repeat region of human ß-Catenin.  
It can be noticed from the results here, the change of the peak intensity as a 
function of the applied AFP with no sign change and consequently absence of 
zero crossing. The absence of zero crossing is due to spin diffusion which 
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indicates that the whole molecule of compound 13 is deeply embedded in the 
binding pocket of the protein and being surrounded by hydrophobic patch. 
 
 
 
 
FIG. 49 Selective AFP-NOESY traces of the protein complex formed between 
Fluorescein sodium and human ß-Catenin. (A) The NOE between H1, H2, H7, H8 and  H4, 
H5  of Fluorescein was measured as a function of AFP spin lock power. (B) The NOE 
between H4', H5', H6' and H1, H2, H7, H8 of Fluorescein was measured as a function of AFP 
spin lock power. (Figure is adapted from Henen et al.97). 
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3.2.5. Isothermal calorimetry (ITC): 
The binding between fluorescein sodium (13) with catenin was measured 
using ITC to detect the thermodynamics of binding. Different concentrations of 
the protein and the ligand have been tried to achieve saturation and considerable 
data. The initial concentrations were 20 µM ß-Catenin : 4 mM of compound 13.  
The measurements were done at 25 ˚C using µ-ITC calorimeter (Microcal). 
Samples of the protein and ligand were all dissolved in the same batch of tris-
buffer to avoid biased results. The ligand was injected from a syringe into the cell 
containing the protein through 20 successive injections. To get rid of the heat 
dilution effect, a blank experiment was done in which the ligand was injected into 
a cell containing the buffer alone and the result was subtracted from the original 
results. Thermodynamic parameters were estimated by non-linear least square 
method using procedures incorporated in the “origin” software package 
(Microcal). 
 
Results & Discussion 
The isotherm showed that the fluorescein sodium is binding to the protein in 
binding ratio (stoichiometry N) 16:1. The dissociation constant (KD) of the 
binding between this ligand and the protein is 79.3 µM. The enthalpy of the 
reaction (∆H) is -3694 cal/mol indicating an exothermic reaction, and the entropy 
of the reaction is 6.25 cal/mol/deg. The raw data and the fit data are shown in 
figure 50(A &B).  
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FIG. 50 The raw data of the calorimetric measurement between 20 µM ß-Catenin and 4 
mM fluorescein sodium (A), and the processed data showing the stoichiometry, binding 
constant, enthalpy and entropy (B). 	  
 
A	  
B	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3.2.6. Dynamic Combinatorial Chemistry:  
Table 3. Virtual dynamic imine system formation 
 
NH2
SO3H
18  
NH2
CH3
Cl
19  
 
O
F
CH=N SO3H
18A  
O
F
CH=N Cl
19A
H3C
 
	  
O
CH=N SO3H
18B  
O
CH=N Cl
19B H3C  
Experimental 
 
103  
 
To probe imine formation reaction for its performance in dynamic 
chemistry, a prototype system was designed and tested for binding to the human 
armadillo repeat region of ß-Catenin. 1D 1H-STD NMR experiments were 
subsequently adopted for binding studies of the library with ß-Catenin.  
Thus the nucleophilic addition reaction between two aldehydes; 4-fluoro-3-
phenoxybenzaldehyde (A) & 4-phenoxybenzaldehyde (B), and two amines; 4-
aminobenzenesulfonic acid (18) & 4-chloro-2-methylaniline (19), resulted in 
spontaneous synthesis of 4 novel different imines in equilibrium with the initial 
building blocks. Each single component in the library was tested separately for 
binding with the targeted protein. Then each single aldehyde with the two amines 
was tested. Eventually the whole (library) was tested. The components of the 
library have been chosen based on their similarity with the two known lead 
compounds; 13 & 14. 
The reactions as well as the measurements were done in the NMR tube at final 
concentration 1 mM of each separate ligand and 30 µM of protein. All the ligands 
were dissolved in deuterated DMSO in stock of 40 mM and the added to protein 
solution to have a sample with final volume 500 µl [ligand(s) concentrations 1mM 
and protein concentration 30 µM at pH=7.4]. All spectra were acquired at 25 °C 
on a Varian INOVA 800 MHz spectrometer. 
 
Results & Discussion 
a- Testing of each single compound (18, 19, A and B). 
A complex of 1 mM 4-chloro-2-methylaniline (19) and 30 µM ß-Catenin 
showed zero STD indicating that this amine doesn't bind to the targeted protein 
(fig. 51) 
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FIG. 51 1D 1H-STD NMR of the protein complex formed between compound 19 and 
human ß-Catenin. Zero STD was obtained (the peaks observed are dispersive peaks can’t 
be phased and result from subtraction artifact). In the blue box, illustration of the 
difference between positive STD and artifact zero-STD. 
 
Moreover, a complex of 1mM 4-aminobenzenesulfonic acid (18) and 30 µM ß-
Catenin showed zero STD indicating that this amine didn’t bind to the targeted 
protein. 
 In addition, a complex of 1mM of 4-fluoro-3-phenoxybenzaldehyde (A) and 30 
µM targeted protein showed positive STD indicating that this aldehyde binds to ß-
Catenin. 
Eventually, a complex of 1mM of 4-phenoxybenzaldehyde (B) and 30 µM 
targeted protein showed positive STD indicating that this aldehyde binds to ß-
Catenin. 
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b- Testing of each aldehyde (A or B) with the 2 amines (18 and 
19). 
Based on the data that showed that both aldehydes (A and B) are binding to 
the targeted protein, while both amines showed no binding to the targeted protein, 
it was noteworthy to test the binding of each aldehyde in the presence of both 
amines. This leads to the formation of two novel imine compounds in each case. 
1D 1H-STD was done to measure the binding and to see the equilibrium between 
the free aldehyde (CHO) peak and the newly formed imine peak (N=CH). 
• 4-Fluoro-3-phenoxybenzaldehyde (A) with amines 18 & 19. 
To 25 µl 20 mM compound A, 12.5 µl of 40 mM compound 18 and 12.5 µl of 
40 mM compound 19 were added to have a final volume of 50 µl in the NMR 
tube. The mixture was kept at room temperature for 20 minutes. To this prepared 
mixture, 450 µl of 33 µM the expressed human ß-Catenin in tris-buffer/10%D2O 
was added to have a final concentration 30 µM protein and 1 mM of each ligand. 
1D 1H-NMR was measured for this mixture. It was observed the reduction in the 
aldehyde peak intensity at 9.82 ppm and the appearance of new imines peak at 
9.20 ppm. This proved the synthesis of two new imines 18A and 19A in 
equilibrium with the starting blocks (fig. 54). In addition, STD-AF value was 
calculated for 0.5 mM of compound 19A to compare it with the value obtained for 
compound 16. Compund 19A showed STD-AF value of 3.64 (i.e. STD-AF for 
compound 16 was 0.63)97. This can be justified by better binding of the newly 
formed imine 19A in comparison to the small fragment 16.  
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FIG. 52 1D 1H-NMR of the reaction between aldehyde A and the 2 amines 18& 19 in 
presence of ß-Catenin. The newly synthesized compounds 18A and 19A showed a new 
imine peak at 9.20 ppm. 
 
The formed protein complex was subjected to 1D 1H-STD NMR to see the 
binding between the newly formed imines and the targeted protein. It was found 
that positive STDs were recorded for the imine. 
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•  4-phenoxybenzaldehyde (B) with amines 18 & 19. 
To 25 µl 20mM compound B in deuterated DMSO, 12.5 µl of 40 mM compound 
18 in deuterated DMSO and 12.5 µl of 40 mM compound 19 in deuterated DMSO  
were added to have a final volume of 50 µl in the NMR tube. The mixture was 
allowed to stand at room temperature for 20 minutes. To this prepared mixture, 
450 µl of 33 µM the synthesized human ß-Catenin in tris-buffer/10%D2O was 
added to have a final concentration 30 µM protein and 1 mM of each ligand. 1D 
1H-NMR was recorded for this mixture. Watching the peaks at 9.82 & 9.29 that 
corresponding to the aldehyde and the imine functional groups respectively 
monitored the equilibrium between aldehyde and the formed imine (fig. 53).  
The formed protein-ligand complex was subjected to 1D 1H-STD NMR to see the 
binding between the newly formed imines and the target protein. It was found that 
positive STDs were recorded for the imines. 
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FIG. 53 1D 1H-NMR of the reaction between aldehyde B and the 2 amines 18 & 19 in 
presence of ß-Catenin. The newly synthesized compounds 18B and 19B showed a new 
imine peak at 9.29 ppm. 
 
c- Testing of the “whole library” (aldehydes A and B) with the 
2 amines (18 and 19). 
It was noteworthy to test how the whole library would behave when we 
have the 2 aldehydes (A and B) with the 2 amines (18 and 19) mixed with the 
target protein.   
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A mixture of deuterated DMSO solutions of 12.5 µl 40 mM compound A, 12.5 µl 
of 40 mM compound B, 12.5 µl of 40 mM compound 18 and 12.5 µl of 40 mM 
compound 19 was prepared to have a final volume of 50 µl in the NMR tube. The 
mixture was allowed to stand at room temperature for 20 minutes. To this 
prepared mixture, 450 µl of 33 µM the human ß-Catenin in tris-buffer/10%D2O 
was added to have a final concentration 30 µM protein and 1 mM of each ligand. 
1D 1H-NMR was recorded for this mixture. It was observed the reduction in both 
aldehyde peaks intensity at 9.82 and 9.84 ppm and the appearance of two new 
imines peaks corresponding to compounds 18A, 18B, 19A and 19B at 9.20 and 
9.29 ppm (fig. 54). The newly formed imines showed positive STD indicating that 
the 4 imines are binding to catenin (fig. 55) 
 
 
FIG. 54 zoomed 1D 1H-NMR of the reaction between aldehydes A and B and the 2 
amines 18 & 19 in presence of ß-Catenin. The newly synthesized compounds 18A,18B, 
19A and 19B  showed new imine peaks at 9.20 and 9.28 ppm. A reduction in aldehyde 
peaks at 9.82 and 9.84 was observed. 
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FIG. 55 1H- STD NMR of the 4 newly formed imines in presence of ß-Catenin showing 
positive STD. 
 
 
d- 19F-NMR for compound 19A 
Compound 19A was tested for binding with armadillo repeat region of ß-
Catenin using 19F-NMR. Firstly, compound 19A (mixture of compound 19 and 
compound A) in 10% DMSO and Tris-buffer was measured using 19F-NMR. It 
showed 3 different peaks at -129.06, -125.9 and -121.9 (corresponding to the E- 
and Z- conformers and the free aldehyde).  The experiment was measured again 
after addition of 30 µM of catenin. The peak at -129.06 got broadened while the 
peak at -125.9 got less affected. Broadening of the 19F peaks is indication of 
binding between compound 19A and catenin. 
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FIG. 56 19F-NMR for compound 19A alone and compound 19A with the targeted protein. 
 
The experiment was repeated for a mixture of 19A, catenin and 60 µM TCF4 and 
for a mixture of 19A, catenin and 1mM sodium 2-phenoxybenzoate (16). It was 
found that in presence of TCF4, the peaks are still broadened indicating that TCF4 
doesn’t substitute 19A from the binding site. On the other hand, in presence of 
sodium 2-phenoxybenzoate (16), the peak at -129.06 got sharper indicating a 
competition between 19A and 16 on the binding site of ß-Catenin. 
O
F
CH=N
H3C
Cl 19A	  
19A+	  Catenin	  
Experimental 
 
112  
 
FIG. 57 19F-NMR peak at -129.06 ppm. Black: 19A alone in tris-buffer. Red: 19A + 
catenin. Green: 19A +catenin+TCF4. Blue: 19A+catenin+ sodium 2-phenoxybenzoate. 
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Structure Summary: 
From the previous data, it was shown that both the free aldehydes (A and 
B) bind to the human armadillo repeat region of ß-Catenin, while the free amines 
(18 and 19) didn't show any binding to the target protein. From these data, and 
from what was previously shown in 1D AFP-NOESY of observed NOEs between 
the protons of the xanthen ring in fluorescein, it can be concluded that 
OXYDIBENZENE moiety is a potential pharmacophore for ß-Catenin ligands 
and when it's present in the compound, the whole compound is embedded in the 
core region of ß-Catenin.  
 
 
 
 
FIG. 58 Oxydibenzene moiety was shown to be a potential pharmacophore in ß-Catenin 
binders. 
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3.2.7. Synthesis of selectively 13C-labelled reductively methylated 
ß-Catenin 
 
Reductive methylation was performed similar to what was described by 
Means and Feeney. The protein was dialyzed into 10 mM HEPES buffer at pH 
7.4. 0.25 ml of 3.2 M borane ammonium complex (NH3-BH3) and 0.5 ml of 3.2 M 
13C-labelled formaldehyde were added to 0.5 ml of 40 µM protein and the reaction 
was incubated under stirring at 4°C. The addition of borane ammonium complex 
and 13C-formaldehyde was repeated and the reaction was incubated for more 2 h. 
After addition of 0.12 ml of 3.2 M borane ammonium complex, the reaction 
mixture was incubated at 4°C with stirring overnight. Adding glycine to 200 mM 
concentration ended the reaction. Dialysis against tri-buffer at pH 7.4 was 
performed to get rid of excess reagents and unwanted products. The sample was 
concentrated to 40µM. Three sets of 2D HSQC NMR experiments were done on 
the 13C-methylated ß-Catenin. All NMR experiments were done on Varian Innova 
600 MHz spectrometer. 
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Table 4: Recording parameters of the performed 2D 1H-13C HSQC 
experiments on the methylated lysine ß-Catenin. 
Spectral width [Hz] F1 x F2 
Number of points F2 (1H) 
Number of increments F1(13C) 
Number of scans 
Decoupler offset Hz (dof) 
5000.0 x 7022 
1024 
115 
24 
-10870 
 
Results & Discussion 
a- 2D 13C-1H HSQC for the free methylated lysine ß-
Catenin: 
For 40µM of the free 13C-methylated ß-Catenin in tris-buffer/10% D2O, 
13C-1H HSQC was measured (fig. 59A). Lysine side chains that are commonly 
found on the protein exterior experience unobstructed rotation. Hence, all 
appeared as one intense peak at 1H, 13C; (2.83, 40.5) ppm. 
The other methylated lysines appeard at 1H, 13C; (2.45, 41.9) ppm, (2.75, 
52.5) ppm, (2.86, 42.5) ppm, (2.95, 46) ppm and (3.00, 46.5) ppm. 
b- 2D 13C-1H HSQC for the methylated lysine ß-Catenin with 
120 µM TCF4 : 
To 40 µM of the free 13C-methylated ß-Catenin in tris-buffer/10% D2O, 
120 µM of TCF4 was added. 13C-1H HSQC was measured (fig. 59B). Lysine side 
chains that are commonly found on the protein exterior appeared as one intense 
peak at 1H, 13C; (2.91, 40.5) ppm. The other methylated lysines appeared at 1H, 
13C; (2.77, 45.00) ppm, (2.75, 52.5) ppm, (2.86, 42.5) ppm, (2.95, 46) ppm and 
(3.00, 46.5) ppm. It was clear that one peak which appeared at 1H, 13C; (2.45, 
41.9) ppm was shifted to 1H, 13C; (2.77, 45.00) ppm when the binding partner 
Experimental 
 
116  
TCF4 was added. In addition, peaks at (2.95, 46) ppm and (3.00, 46.5) ppm had 
less intensity upon binding with TCF4. 
 
c-2D 13C-1H HSQC for the methylated lysine ß-Catenin with 1 
mM sodium 2-phenoxybenzoate (16): 
From previously done experiments, we proved that fluorescein analogs bind to 
the core region of the synthesized ß-Catenin. It was of great interest to know if 
these compounds bind to the same binding site(s) as TCF4. In order to do this, 40 
µM of the free 13C-methylated ß-Catenin in tris-buffer/10% D2Owas added to 1 
mM of sodium 2-phenoxybenzoate (16). 13C-1H  HSQC was measured. 
Lysine side chains that are commonly found on the protein exterior appeared as 
one intense peak at 1H, 13C; (2.91, 40.5) ppm. The other methylated lysines 
appeared at 1H, 13C; (2.81, 45.00) ppm, (2.75, 52.5) ppm, (2.75, 58.5) ppm, (2.86, 
42.5) ppm, (2.95, 46) ppm and (3.00, 46.5) ppm. 
It was proved that binding to TCF4 or sodium 2-phenoxybenzoate (29) shifted the 
lysine peak at 1H, 13C; (2.45, 41.9) ppm to the same new position. Moreover, 
binding with compound 2, leaded to appearance of new peak at 1H, 13C; (2.75, 
58.5) ppm which could be belonging to one of the exterior lysines was included in 
binding (fig. 59C) 
It can be concluded, that both TCF4 and sodium 2-phenoxybenzoate have similar 
binding sites on the armadillo repeat region of ß-Catenin. 
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FIG. 59 13C-1H HSQC spectra of  (A) Free form of methylated catenin, (B) methylated 
catenin with TCF4, and (C) methylated catenin with sodium 2-phenoxybenzoate. The 
peaks of lysines that are on the surface of the protein appeared on top of each other and 
highlighted with the triangle. The lysine peak that is highlighted with square shifted upon 
binding to TCF4 and to sodium 2-phenoxybenzoate as well. The peak highlighted with 
the circle appeared only upon binding with phenoxybenzoate. 
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3.2.8. Backbone assignment of TCF4 and its truncated versions 
using 2D and 3D NMR experiments 
Data collection for residue assignment of TCF4 were done on a Varian Unity 500 
& 600 MHz Spectrometers at 25°C. Data were collected from a 15N- and 13C-
labeled TCF4 which was prepared at a final concentration of 1 mM (pH 7.4, 4.5 
and 2). Final recording parameters for NMR experiments are depicted in table 5. 
Table 5. Recording parameters of the performed assignment NMR 
experiments. 
2D 1H-15N-HSQC  
Spectral width [Hz] F1 x F2 
Number of points F2 (1H) 
Number of increments F1(14N) 
Number of scan 
5000.0 x 7022 
1024 
115 
24 
3D HNCA  
Spectral width [Hz] F1 x F2 x F3 
Number of points F3 (1H) 
Number of increments F1(13C) 
Number of increments F2(14N) 
Number of scans 
4500.0 x 1500 x 69999.7 
720 
80 
28 
24 
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3D HNCOCA  
Spectral width [Hz] F1 x F2 x F3 
Number of points F3 (1H) 
Number of increments F1(13C) 
Number of increments F2(14N) 
Number of scans 
4500.0 x 1500.01 x 6999.7 
558 
50 
36 
24 
3D HNCACB  
Spectral width [Hz] F1 x F2 x F3 
Number of points F3 (1H) 
Number of increments F1(13C) 
Number of increments F2(14N) 
Number of scans 
8000.0 x 1800.01 x 6999.7 
896 
90 
28 
24 
3D HNCO  
Spectral width [Hz] F1 x F2 x F3 
Number of points F3 (1H) 
Number of increments F1(13C) 
Number of increments F2(14N) 
Number of scans 
2000.0 x 1500.01 x 6999.7 
560 
50 
36 
20 
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3D HNCACO  
Spectral width [Hz] F1 x F2 x F3 
Number of points F3 (1H) 
Number of increments F1(13C) 
Number of increments F2(14N) 
Number of scans 
2000.0 x 1500.01 x 6999.7 
562 
50 
28 
32 
 
For assignment of TCF4, the spectra measured at pH=7.4 were so ambiguous, so 
we moved down with the pH value to 4.5 which gave the best spectral data.  In 
addition, the two truncated versions of TCF4; N-terminal and C-terminal peptides 
were also assigned at the same pH and the values obtained were compared with 
those of the full length. Moreover, a comparison between the chemical shift 
values of the assigned residues and the predicted ones of random coil was done to 
extract the possible secondary structure of TCF4 in the unbound form. 
Table 6 shows the assigned chemical shift values for the full length TCF4 and the 
peptides. 
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Table 6. Backbone assignment of 15N-13C labeled wild type-TCF4 and its 
mutants 
 
Full 
Res # res H N Cα Cβ 
Pept 
Res # H N Cα Cβ 
4 Leu 8.56 124.67 54.94 41.91      
5 Asn 8.63 119.71 52.96 38.44      
6 Gly 8.44 109.12 44.96 -      
9 Gly 8.46 109.66 44.95 -      
10 Asp 8.34 120.3 53.9 40.65      
11 Asp - - - - 11 8.36 121.48 54.16 40.97 
12 Leu 8.28 122.97 55.08 41.58 12 8.26 
123.5
6 55.48 41.78 
13 Gly 8.48 109.47 45.04 - 13 8.48 109.5 45.09 - 
14 Ala 8.13 123.56 52.26 18.92 14 8.09 
123.5
2 52.36 18.2 
15 Asn 8.19 118.92 53.85 40.52 15     
16 Asp 8.29 120.92 54.18 41.56 16 8.27 
120.8
7 54.86 40.95 
17 Glu 8.32 120.7 56.31 29.5 17 8.33 121.01 56.47 28.91 
18 Leu 8.19 122.76 54.92 41.66 18 8.2 
122.7
6 55.25 41.09 
19 Ile 8.04 122.08 60.6 38.21 19 8.02 
122.0
4 61.07 38.91 
20 Ser - - - - 20 8.42 117.83 - - 
21 Phe 8.29 122.7 55.23 41.52 21 8.26 123.01 57.78 41.85 
22 Lys 8.63 - 52.96 38.4 22 8.16 123.57 56.15 - 
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23 Asp 8.35 122.3 53.97 40.65 23 8.37 122.63 54.19 41.21 
24 Glu 8.73 122.11 56.78 29.3 24 8.48 
122.1
4 56.97 30.01 
25 Gly 8.57 109.79 44.91 - 25     
26 Glu 8.26 120.65 56.18 29.6 26 8.24 
120.6
2 56.35 29.06 
27 Gln 8.48 121.31 55.51 29.04 27 8.47 
121.5
4 55.31 29.63 
28 Glu 8.45 122.49 56.37 29.49 28 8.5 123.3 56.72 30.33 
29 Glu 8.43 123.09 55.96 32.53      
30 Lys          
31 Ser          
32 Ser          
33 Glu 8.52 122.77 56.14 29.54      
34 Asn 8.43 119.38 52.92 38.5      
35 Ser 8.34 116.54 58.31 63.14      
36 Ser 8.42 117.99 58.08 63.18      
37 Ala 8.27 125.75 52.45 18.8 37 8.25 125.7 52.41 - 
38 Glu 8.29 119.59 56.45 29.33 38 8.26 
119.5
5 56.51 - 
39 Arg 8.19 121.42 55.98 30.51 39 8.15 
121.2
8 55.94 - 
40 Asp 8.39 121.41 54.12 40.4 40 8.35 
121.2
8 54.15 - 
41 Leu 8.15 122.83 55.08 - 41 8.12 
122.9
1 55 - 
42 Ala 8.2 123.49 52.49 18.76 42 8.19 
123.5
1 52.49 - 
43 Asp 8.18 119.29 53.89 40.45 43 8.14 
119.0
7 53.92 - 
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44 Val 7.99 120.24 62.09 31.92 44 7.94 
120.3
7 62.31 - 
45 Lys 8.39 124.07 56.28 32.2 45 8.35 
124.2
4 56.11 - 
46 Ser 8.32 116.17 58.38 62.98 46     
47 Ser     47     
48 Leu 8.18 123.69 55.19 41.73 48 8.16 
123.5
4 54.9 - 
49 Val 8 120.44 62.05 32.17 49 7.97 
120.1
8 61.76 - 
50 Asn     50 8.48 122.84 52.79 - 
51 Glu 7.84 127.08 58.74 - 51 7.91 
126.4
6 57.64 30.84 
52 Ser          
53 Glu          
54 Thr 8.06 113.48 62.36 69.01      
55 Asn 8.05 113.52 - -      
56 Lys          
57 Asn          
58 Trp 8 119.09 57.04 29.22      
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FIG. 60 15N-1H- HSQC of full length TCF4 at pH=4.5, 600 MHz. The peaks assignment 
is shown on top of each peak. 
 
For the mapping of the possible secondary structure elements, the random coil 
chemical shift values were compared with that of the calculated from assignment. 
The Cα secondary chemical shift values are plotted as a function of residue 
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umber. It can be clearly seen from this, that there’s no significant difference 
between both which proves that TCF4 in the unbound form act as a random coil 
and lacks any definite secondary structure. The predicted chemical shift values for 
TCF4 were extracted using the online project (NCIDP) developed by Molecular 
Dynamics and NMR Group / University of Groningen, The Netherlands100.  
 
FIG. 61 Cα chemical shift difference between the assigned TCF4 peptides at pH=4.5 and 
the predicted random coil chemical shift values. The figures shows the absence of 
secondary structure elements from the full length free TCF4. 
 
3.2.9. Secondary structure propensity for TCF4 (SSP) 
From the pdb structure “entry 1JDH”, it’s possible to observe that TCF4 
has structural variability. It forms 2 alpha helices regions upon binding to ß-
Catenin. These areas are residues 21-31 and 38-49. This structure modulation on 
TCF4 can be rationalized based on the environmental effect, which is the binding 
partner in this case. The residues on catenin that are close to these regions on 
TCF4, which form alpha helices, are mainly lysine residues. When these residues 
are protonated, they are acting as conjugated acid (H-bond donor or simply H-
donor like any acid), and this in turn results in stabilizing the formation of alpha-
helix structures. Hence, at low pH, which is mimicking of the presence of 
protonated basic residues, partial protonation to the negatively charged side chains 
on TCF4 stabilizes the formation of alpha helix structures. Figure number 62 
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shows the structure of the complex of catenin-TCF4 illustrating the basic residues 
on catenin that approach the alpha helices on TCF4.  
	  
FIG. 62 Crystal structure of β-Catenin-TCF4 complex (pdb entry: 1JDH). The catenin is 
highlighted in green, TCF4 in blue and the basic residues on catenin that are in contact 
with TCF4 are in orange. 
 
In order to investigate this hypothesis and to predict the possible secondary 
structure elements in TCF4, the assignment of the protein was also done at pH=2 
(to mimic the partial-protonation event upon binding). The Chemical shifts of N, 
1HN, Cα and Cβ were extracted and compared regarding SSP with the ones 
obtained at pH=4.5 using the pearl script described by Marsh et al7.  It was shown 
that at pH=2, two regions on TCF4 (residues 23-27, and residues 36-42) showed 
alpha helix secondary structure propensity, while the rest of residues are in beta or 
random coil propensity. These findings match with the crystal structure in which 
two regions of TCF4 form alpha helices upon (partial protonation=binding). 
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FIG. 63 Plot of the difference in secondary structure propensity of TCF4 between pH 2 
and pH 4.5. It’s shown that at pH=2, regions of residues 23-27 and 36-42 have alpha 
helix propensity in contrast to the same regions at pH=4.5.  
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3.2.10. Crystallization & structure elucidation of armadillo repeat 
region of human ß-Catenin 
The following robotics have been employed for the crystallization work: a) 
an Alchemist II liquid handling robot (Rigaku) for pipetting of non-commercial 
24-well Linbro format (hanging drop plates), b) a Phoenix liquid handling system 
(Art Robbins Instruments) for preparation 96-well crystallization trials using 
commercially available conditions, c) a Minstrel DT imaging system (Rigaku) 
equipped with the Atlantis software for automatic imaging. Images were screened 
using the CrystalTrak software (Rigaku). For commercial screens and 
optimizations in 96-well format pipetted by the Phoenix liquid handling system, 
3-well IntelliPlates (Art Robbins instruments) were used. 24-well optimizations, 
which were set up by hand, were performed in 24-well Linbro format plates, 
pregreased (Crystalgen). Crystals were stored in a crystallization room at either 22 
˚C. 
The protein sample was expressed and purified in tris-buffer and concentrated to 
6.8mg/ml concentration. Different commercial JCSG conditions have been tried 
(QIAGEN). The protein was crystallized upon using screen in the following 
conditions: 0.2 M potassium thiocyanate, and 20 % w/v polyethyleneglycol 3350 
at pH=7.4. Optimization windows were tried to get the optimal crystals. The 
crystals obtained from condition of monoethylene polyethyleneglycol 20% w/v 
2000 + potassium thiocynate 0.1 M were sent for data collection. The crystals 
were kept in a solution of 40% PEG 3350 and 0.1 M potassium thiocyanate for 
cryogenic protection.  
Data collection: 
Diffraction data were collected either in the laboratory using a Bruker 
Microstar (Bruker AXS Inc.) rotating anode at 1.54 Å wavelength or using ESRF 
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beamline (Grenoble, France) at wavelength 0.939 Å.  
The phase problem was solved using Zebra fish ß-Catenin as a model for 
molecular replacement (PDB entry: 2Z6G)101 by software PHASER102. Model 
refinement was done using phenix.refine from the PHENIX suite103. The built 
model validation was done using a web server Molprobity104. Details of data 
collection and refinement statistics are illustrated in table 7. 
 
Table 7: Data collection and refinement statistics for human armadillo repeat 
region of ß-Catenin. 
Source ID14-4 (ESRF) 
Wavelength (Å) 0.939 
Resolution (Å) 45-2.4 (245-2.4) 
Space group P212121 
Unit cell (Å) 
a= 51.326 
b= 73.62 
c=133.63 
Molecules/ a.u. 1 
Unique reflections 20594 (1356) 
Completeness (%) 99.1 (90.2) 
I/ σ(I) 10.6 (1.8) 
Software used for integration XDS 
Software used for scaling XSCALE 
Software used for phasing PHASER 
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Rcrys/Rfree 0.183/0.266 
R.M.S.D bonds (Å) 0.008 
R.M.S.D angles (Å) 1.13 
Average B factor protein (Å2) 52.06 
Average B factor solvent (Å2) 45.6 
Software used for refinement Refmac/Phenix 
 
Results & Discussion 
The structure of human armadillo repeats region of ß-Catenin was solved 
at a resolution 2.4 Å. After solving the phase problem using molecular 
replacement and building the refined model, the structure showed conserved 12 
repeats of alpha helices forming a super helix, each repeat is 3 alpha helices. The 
region of residues 559-567 showed different conformations although this isn’t the 
binding site of TCF4. 
 
FIG. 64 Structure of the solved free human armadillo repeat domain of ß-Catenin at 
resolution 2.4 A˚ is shown in blue, while the structure of the human one bound to TCF4 is 
shown in red, TCF4 is shown in green (pdb entry: 1JPW). The area of residues between 
559-567 showed different conformation (highlighted in light blue for the free form and in 
brown for the bound form). 
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Query  133  HAVVNLINYQDDAELATRAIPELTKLLNDEDQVVVNKAAVMVHQLSK  179 
            HAVVNLINYQDDAELATRAIPELTKLLNDEDQVVVNKAAVMVHQLSK 
Sbjct  134  HAVVNLINYQDDAELATRAIPELTKLLNDEDQVVVNKAAVMVHQLSK  180 
 
Query  180  KEASRHAIMRSPQMVSAIVRTMQNTNDVETARCTSGTLHNLSHHREGLLAIFKSGGIPAL  239 
            KEASRHAIMRSPQMVSAIVRTMQNTNDVETARCT+GTLHNLSHHREGLLAIFKSGGIPAL 
Sbjct  181  KEASRHAIMRSPQMVSAIVRTMQNTNDVETARCTAGTLHNLSHHREGLLAIFKSGGIPAL  240 
 
Query  240  VNMLGSPVDSVLFHAITTLHNLLLHQEGAKMAVRLAGGLQKMVALLNKTNVKFLAITTDC  299 
            V+MLGSPVDSVLF+AITTLHNLLLHQEGAKMAVRLAGGLQKMVALLNKTNVKFLAITTDC 
Sbjct  241  VKMLGSPVDSVLFYAITTLHNLLLHQEGAKMAVRLAGGLQKMVALLNKTNVKFLAITTDC  300 
 
Query  300  LQILAYGNQESKLIILASGGPQALVNIMRTYTYEKLLWTTSRVLKVLSVCSSNKPAIVEA  359 
            LQILAYGNQESKLIILASGGPQALVNIMRTYTYEKLLWTTSRVLKVLSVCSSNKPAIVEA 
Sbjct  301  LQILAYGNQESKLIILASGGPQALVNIMRTYTYEKLLWTTSRVLKVLSVCSSNKPAIVEA  360 
 
Query  360  GGMQALGLHLTDPSQRLVQNCLWTLRNLSDAATKQEGMEGLLGTLVQLLGSDDINVVTCA  419 
            GGMQALGLHLTDPSQRLVQNCLWTLRNLSDAATKQEGMEGLLGTLVQLLGSDDINVVTCA 
Sbjct  361  GGMQALGLHLTDPSQRLVQNCLWTLRNLSDAATKQEGMEGLLGTLVQLLGSDDINVVTCA  420 
 
Query  420  AGILSNLTCNNYKNKMMVCQVGGIEALVRTVLRAGDREDITEPAICALRHLTSRHQDAEM  479 
            AGILSNLTCNNYKNKMMVCQVGGIEALVRTVLRAGDREDITEPAICALRHLTSRHQ+AEM 
Sbjct  421  AGILSNLTCNNYKNKMMVCQVGGIEALVRTVLRAGDREDITEPAICALRHLTSRHQEAEM  480 
 
Query  480  AQNAVRLHYGLPVVVKLLHPPSHWPLIKATVGLIRNLALCPANHAPLREQGAIPRLVQLL  539 
            AQNAVRLHYGLPVVVKLLHPPSHWPLIKATVGLIRNLALCPANHAPLREQGAIPRLVQLL 
Sbjct  481  AQNAVRLHYGLPVVVKLLHPPSHWPLIKATVGLIRNLALCPANHAPLREQGAIPRLVQLL  540 
 
Query  540  VRAHQDTQRRTSMGGTQQQFVEGVRMEEIVEACTGALHILARDIHNRIVIRGLNTIPLFV  599 
            VRAHQDTQRRTSMGGTQQQFVEGVRMEEIVE+CTGALHILARD+HNRIVIRGLNTIPLFV 
Sbjct  541  VRAHQDTQRRTSMGGTQQQFVEGVRMEEIVEGCTGALHILARDVHNRIVIRGLNTIPLFV  600 
 
Query  600  QLLYSPIENIQRVAAGVLCELAQDKEAAEAIEAEGATAPLTELLHSRNEGVATYAAAVLF  659 
            QLLYSPIENIQRVAAGVLCELAQDKEAAEAIEAEGATAPLTELLHSRNEGVATYAAAVLF 
Sbjct  601  QLLYSPIENIQRVAAGVLCELAQDKEAAEAIEAEGATAPLTELLHSRNEGVATYAAAVLF  660 
 
Query  660  RMSEDKPQDYK  670 
            RMSEDKPQDYK 
Sbjct  661  RMSEDKPQDYK  671 
FIG. 65 alignment of Zebra fish catenin (query) and the human catenin (sbjct). The 
different residues are highlighted with red. 
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Zusammenfassung	  
	  Abweichungen	   im	   Wnt/Beta-­‐Catenin	   Signalweg	   kommen	   in	   vielen	  verschiedenen	   menschlichen	   Krebserkrankungen	   vor.	   Unter	   anderem	   wird	  dieser	   Signalweg	   in	   Darm-­‐	   und	   Eierstockkrebs	   aktiviert.	   Aus	   diesem	   Grund	  haben	   Inhibitoren	   der	   TCF4/Beta-­‐Catenin	   Interaktion	   großes	   Potential	   als	  Antitumormittel.	   Mit	   Hilfe	   des	   vor	   kurzem	   beschriebenen	   „Meta-­‐Structure“	  Ansatzes	   haben	  wir	   eine	  Reihe	   von	   niedermolekularen	  Molekülen	   identifiziert,	  die	  an	  Beta-­‐Catenin	  binden	  und	  als	  Ausgnagspunkt	  für	  zukünftige	  Entwicklungen	  dienen	   könnten.	   Um	   diese	   Interaktionen	   zu	   testen,	   wurden	   verschiedene	  Methoden	  angewandt:	  1D	  1H-­‐STD,	  1D	  AFP	  NOESY,	  2D	  NOESY	  und	  19F-­‐NMR.	  Auch	  die	   Fähigkeit	   der	   neu	   identifizierten	   Liganden	   mit	   dem	   bekannten	  Bindungspartner	  TCF4	  von	  Beta-­‐Catenin	  zu	  konkurrieren	  wurde	  getestet.	  Zur	   weiteren	   Untersuchung	   der	   Interaktionen	   und	   um	  weitere	   neue	   Liganden	  synthetisieren	   und	   identifizieren	   zu	   können,	  wurde	   ein	   sogenannter	   „Dynamic	  Combinatorial	   Library“	   Ansatz	   (Dynamische,	   kombinierbare	  Chemikalienbibliothek)	   adaptiert	   und	   mithilfe	   .	   Weiters	   wurden	   zwei-­‐	   und	  dreidimensionale	   NMR-­‐Experimente	   durchgeführt,	   mit	   welchen	   die	   1N-­‐15H	  Signale	  des	  TCF4	  Proteinrückgrats,	   und	  zweier	   separate	  Teile	  hiervon,	  bei	  pHs	  von	   4,5	   und	   2,0	   zugeordet	   werden	   konnten.	   Ein	   Vergleich	   der	   so	   bestimmten	  Frequenzen	   mit	   den	   errechneten	   Werten	   eines	   theoretischen,	   gänzlich	  unstrukturierten	   Proteins	   gleicher	   Aminosäuresequenz	   („Secondary	   Structure	  Propensity“)	   erlaubte	   es,	   Aussagen	   über	   die	   Wahrscheinlichkeit	   von	  Sekundärstrukturen	  bei	  verschiedenen	  pH-­‐Werten	  zu	  machen.	  Zusätzlich	  zu	  der	  Untersuchung	  neuer	  Liganden	  wurde	  auch	  die	  Struktur	  des	  TCF4/Beta-­‐Catenin	  Komplexes	  näher	  untersucht.	  Hierfür	  wurden	  sowohl	  röntgenkristallographische	  Experimente	   verwendet,	   als	   auch	   die	   selektive	   Reduzierung	   von	   Lysin-­‐Seitenkette	  mit	   13HCHO,	   	   welche	   ein	  Messen	   des	   daraus	   resultierenden	   13C-­‐1H	  Spektrums	  erlaubt.	  Um	  die	  Relevanz	  meiner	  Untersuchungen	  zu	  unterstreichen,	  werden	   die	   sich	   ergebenden	   Möglichkeiten	   für	   die	   Entwicklung	   eines	   neuen	  Antitumormittels	  mit	  möglichst	  hohem	  Sicherheitsprofil	  erörtert.	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